2024/01/31 更新

写真a

オオエ チサト
大江 知里
OHE CHISATO
担当
大学院医学研究科 臨床医科学専攻 准教授
医学部 医学科
職名
准教授
所属
医学研究院
所属キャンパス
阿倍野キャンパス

担当・職階

  • 大学院医学研究科 臨床医科学専攻 

    准教授  2023年07月 - 継続中

  • 医学部 医学科 

    准教授  2023年07月 - 継続中

取得学位

  • 医学博士 ( 関西医科大学 )

研究分野

  • ライフサイエンス / 人体病理学

研究キーワード

  • 治療選択

  • バイオマーカー

  • 腎泌尿器系腫瘍

  • 遺伝子異常

  • 免疫組織化学

  • 組織形態

  • 腫瘍診断

研究概要

  • 日常診療において確定診断を担う病理医の立場から、診療上の問題点の解決に繋がる臨床病理学的研究に力を入れている。特に、がんの遺伝子異常と関連する蛋白発現や組織形態・病理学的予後因子の相関を検討することで、予後予測や新たな治療戦略に繋がる病理学的バイオマーカーの確立を目指している。

所属学協会

  • 日本病理学会

  • 日本臨床細胞学会

  • 日本臨床検査医学会

  • 国際病理アカデミー日本支部

  • 一般社団法人 腎癌研究会

  • 日本泌尿器腫瘍学会

  • 日本泌尿器病理研究会

▼全件表示

委員歴(学外)

  • ゲノム診療用病理組織検体取扱い規約策定ワーキンググループ委員   日本病理学会  

    2022年04月 - 継続中 

  • 癌取扱い規約委員会委員   日本病理学会  

    2022年04月 - 継続中 

  • 学術評議員   一般社団法人腎癌研究会  

    2021年04月 - 継続中 

  • 近畿支部学術委員   日本病理学会  

    2021年04月 - 継続中 

  • 細胞診ガイドライン改訂ワーキンググループ泌尿器小委員会委員   日本臨床細胞学会  

    2021年01月 - 2023年06月 

  • 病理専門医試験実施委員   日本病理学会  

    2019年11月 - 2020年10月 

  • 学術評議員   日本病理学会  

    2019年04月 - 継続中 

  • 腎癌取扱い規約第5版改訂委員   日本泌尿器科学会/日本病理学会/日本医学放射線学会  

    2019年04月 - 2020年12月 

  • 理事   泌尿器細胞診カンファレンス  

    2018年04月 - 継続中 

  • コンサルテーションシステム腎尿路領域コンサルタント   日本病理学会  

    2017年04月 - 継続中 

▼全件表示

受賞歴

  • 日本病理学会症例研究賞

    2023  

  • 一般社団法人加多乃会 「笹川美年子賞」

    2023  

  • 関西医科大学 教員評価優秀賞

    2023  

  • Best Doctors in Japan 2022-2023

    2022  

  • 関西医科大学 女性医師奨励賞(アプリコット賞)

    2022  

  • 公益財団法人金原一郎記念医学医療振興財団 研究交流助成受賞

    2022  

  • 関西医科大学 教員評価優秀賞

    2022  

  • Best Doctors in Japan 2020-2021

    2020  

  • 日本病理学会 英国病理学会派遣

    2020  

  • 公益財団法人大阪対がん協会 がん研究助成奨励金受賞

    2020  

  • 関西医科大学 教育奨励賞

    2020  

  • 一般社団法人加多乃会 「加多乃賞」

    2019  

  • 日本病理学会 学術奨励賞

    2019  

  • 関西医科大学 教育奨励賞

    2019  

  • 関西医科大学 教育奨励賞

    2018  

  • 関西医科大学 教員評価優秀賞

    2018  

  • 公益財団法人上原記念生命科学財団 海外留学助成リサーチフェローシップ受賞

    2015  

  • 公益財団法人金原一郎記念医学医療振興財団 研究交流助成受賞

    2014  

  • 日本病理学会近畿支部 学術奨励賞公募部門

    2013  

▼全件表示

職務経歴(学外)

  • 関西医科大学医学部 病理学講座   准教授

    2022年12月 - 2023年06月

  • 関西医科大学 臨床病理学講座   講師

    2018年07月 - 2022年11月

  • 米国南カリフォルニア大学 泌尿器部門   客員研究員

    2016年02月 - 2017年01月

  • 米国Cedars-Sinai Medical Center 病理臨床検査部門   客員研究員

    2015年02月 - 2016年01月

  • 関西医科大学 臨床検査医学講座/附属病院病理科   助教

    2007年09月 - 2015年01月

  • 関西医科大学附属病院   臨床初期研修医

    2005年04月 - 2007年08月

▼全件表示

論文

  • Hypoxia-inducible factor 2α protein and mRNA expression correlate with histomorphological features in clear cell renal cell carcinoma 査読

    Pham T, Ohe C, Yoshida T, Nakamoto T, Kinoshita H, Tsuta K.

    Pathology Research and Practice   251   154841   2023年11月( ISSN:03440338

     詳細を見る

    担当区分:責任著者   国際・国内誌:国際誌  

    DOI: 10.1016/j.prp.2023.154841

    PubMed

  • Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma 査読

    Yoshida T, Ohe C, Nakamoto T, Kinoshita H.

    Int J Urol   2023年06月

  • The academic impact and value of an international online surgery lecture series. 査読

    Daisuke Hashimoto, Aiste Gulla, Sohei Satoi, Tomohisa Yamamoto, So Yamaki, Yuki Matsui, Chisato Ohe, Makoto Yamasaki, Madoka Hamada, Tsukasa Ikeura, Masaaki Shimatani, Raoul Breugelmans, Algirdas Utkus, Tomas Poskus, Arturas Samuilis, Marius Miglinas, Arvydas Laurinavicius, Koichi Tomoda, Vaiva Hendrixson, Mitsugu Sekimoto, Kestutis Strupas

    Surgery today   1 - 5   2023年02月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国内誌  

    Due to the worldwide travel restrictions caused by the 2019 coronavirus disease pandemic, many universities and students lost opportunities to engage in international exchange over the past 2 years. Teleconferencing systems have thus been developed to compensate for severe travel restrictions. Kansai Medical University in Japan and Vilnius University in Lithuania have a collaborative research and academic relationship. The two universities have been conducting an online joint international surgery lecture series for the medical students of both universities. Fifteen lectures were given from October 2021 to May 2022. The lectures focused on gastrointestinal surgery, gastroenterology, radiology, pathology, genetics, laboratory medicine, and organ transplantation. A survey of the attendees indicated that they were generally interested in the content and satisfied with attending this lecture series. Our efforts were successful in providing Japanese and Lithuanian medical students with the opportunity to engage in international exchange through lectures held in each other's countries.

    DOI: 10.1007/s00595-023-02660-6

    PubMed

  • Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study 査読

    Tamada Satoshi, Nozawa Masahiro, Ohba Kojiro, Mizuno Ryuichi, Takamoto Atsushi, Ohe Chisato, Yoshimoto Takuya, Nakagawa Yuki, Fukuyama Tamaki, Matsubara Nobuaki, Kimura Go, Tomita Yoshihiko, Nonomura Norio, Eto Masatoshi

    International Journal of Clinical Oncology   28 ( 2 )   289 - 298   2023年02月( ISSN:1341-9625

  • Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study 査読

    Tsuzuki T, Ohe C, Osawa T, Yasuda Y, Tanaka T, Anai S, Kimura G, Yamana K, Hatakeyama S, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H.

    Pathology   55 ( 1 )   31 - 39   2023年02月

     詳細を見る

    担当区分:責任著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

  • Hypoxia inducible factor‐1 activator munc‐18‐interacting protein 3 promotes tumour progression in urothelial carcinoma 査読

    Junichi Ikeda, Chisato Ohe, Noritaka Tanaka, Takashi Yoshida, Ryoichi Saito, Naho Atsumi, Takashi Kobayashi, Hidefumi Kinoshita, Koji Tsuta, Takeharu Sakamoto

    Clinical and Translational Discovery   3 ( 1 )   2023年01月( ISSN:2768-0622

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ctd2.158

    その他URL: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ctd2.158

  • Deep learning-based predictions of clear and eosinophilic phenotypes in clear cell renal cell carcinoma 査読 国際共著

    Ohe C, Yoshida T, Amin MB, Uno R, Atsumi N, Yasukochi Y, Ikeda J, Nakamoto T, Noda Y, Kinoshita H, Tsuta K, Higasa K.

    Hum Pathol   131   68 - 78   2023年01月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

  • Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes. 査読 国際共著

    Chisato Ohe, Takashi Yoshida, Mahul B Amin, Naho Atsumi, Junichi Ikeda, Kazuho Saiga, Yuri Noda, Yoshiki Yasukochi, Riuko Ohashi, Haruyuki Ohsugi, Koichiro Higasa, Hidefumi Kinoshita, Koji Tsuta

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc   35 ( 6 )   816 - 824   2022年06月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    The prognostic significance of an architectural grading system for clear cell renal cell carcinoma (ccRCC) has recently been demonstrated. The present study aimed to establish a vascularity-based architectural classification using the cohort of 436 patients with localized ccRCC who underwent extirpative surgery and correlated the findings with conventional pathologic factors, gene expression, and prognosis. First, we assessed architectural patterns in the highest-grade area on hematoxylin and eosin-stained slides, then separately evaluated our surrogate score for vascularity. We grouped nine architectural patterns into three categories based on the vascular network score. "Vascularity-based architectural classification" was defined: category 1: characterized by enrichment of the vascular network, including compact/small nested, macrocyst/microcystic, and tubular/acinar patterns; category 2: characterized by a widely spaced-out vascular network, including alveolar/large nested, thick trabecular/insular, papillary/pseudopapillary patterns; category 3: characterized by scattered vascularity without a vascular network, including solid sheets, rhabdoid and sarcomatoid patterns. Adverse pathological prognostic factors such as TNM stage, WHO/ISUP grade, and necrosis were significantly associated with category 3, followed by category 2 (all p < 0.001). We successfully validated the classification using The Cancer Genome Atlas (TCGA) cohort (n = 162), and RNA-sequencing data available from TCGA showed that the angiogenesis gene signature was significantly enriched in category 1 compared to categories 2 and 3, whereas the immune gene signature was significantly enriched in category 3 compared to categories 1 and 2. In univariate analysis, vascularity-based architectural classification showed the best accuracy in pathological prognostic factors for predicting recurrence-free survival (c-index = 0.786). The predictive accuracy of our model which integrated WHO/ISUP grade, necrosis, TNM stage, and vascularity-based architectural classification was greater than conventional risk models (c-index = 0.871 vs. 0.755-0.843). Our findings suggest that the vascularity-based architectural classification is prognostically useful and may help stratify patients appropriately for management based on their likelihood of post-surgical recurrence.

    DOI: 10.1038/s41379-021-00982-9

    PubMed

  • Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis 査読

    Yoshida T, Ohe C, Ito K, Takada H, Saito R, Kita Y, Sano T, Tsuta K, Kinoshita H, Kitamura H, Nishiyama H, Kobayashi T; Japan Urological Oncology Group.

    Cancer immunology, immunotherapy : CII   71 ( 11 )   2815 - 2828   2022年04月( ISSN:0340-7004

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1007/s00262-022-03204-6

  • Adrenal Tumor With Thrombus in the Inferior Vena Cava 査読

    Yoshida T, Ohe C, Sato G, Kono Y, Saito R, Matsuda T, Kinoshita H.

    Urology   160   17 - 18   2022年02月( ISSN:0090-4295

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1016/j.urology.2021.11.006

  • PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma 査読

    Saiga K, Ohe C, Yoshida T, Ohsugi H, Ikeda J, Atsumi N, Noda Y, Yasukochi Y, Higasa K, Taniguchi H, Kinoshita H, Tsuta K.

    Cancers   14 ( 4 )   1062   2022年02月( ISSN:2072-6694

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.3390/cancers14041062

    PubMed

  • Histologic-Based Tumor-Associated Immune Cells Status in Clear Cell Renal Cell Carcinoma Correlates with Gene Signatures Related to Cancer Immunity and Clinical Outcomes 招待 査読

    Ohe C, Yoshida T, Ikeda J, Tsuzuki T, Ohashi R, Ohsugi H, Atsumi N, Yamaka R, Saito R, Yasukochi Y, Higasa K, Kinoshita H, Tsuta K.

    Biomedicines   10 ( 2 )   323   2022年01月( ISSN:2227-9059

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.3390/biomedicines10020323

    PubMed

  • Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma 査読

    Yoshida T, Ohe C, Ikeda J, Atsumi N, Saito R, Taniguchi H, Ohsugi H, Sugi M, Tsuta K, Matsuda T, Kinoshita H

    The Journal of Pathology: Clinical Research   6 ( 6 )   590 - 603   2021年11月( ISSN:2056-4538

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1002/cjp2.232

  • Predictors of postoperative recurrence in patients with non-metastatic pT3a renal cell carcinoma 査読

    Ohsugi H, Ohe C, Yoshida T, Ikeda J, Sugi M, Kinoshita H, Matsuda T.

    International journal of urology   28 ( 10 )   1060 - 1066   2021年10月( ISSN:0919-8172

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1111/iju.14648

  • Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade 査読

    Yoshida T, Ohe C, Ikeda J, Atsumi N, Ohsugi H, Sugi M, Higasa K, Saito R, Tsuta K, Matsuda T, Kinoshita H

    JOURNAL FOR IMMUNOTHERAPY OF CANCER   9 ( 9 )   e002922 - e002922   2021年09月( ISSN:2051-1426

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1136/jitc-2021-002922

  • Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases

    Ikeda Junichi, Ohe Chisato, Ohsugi Haruyuki, Matsuda Tadashi, Tsuta Koji, Kinoshita Hidefumi

    Pathology International   71 ( 9 )   621 - 626   2021年09月( ISSN:1320-5463

     詳細を見る

    国際・国内誌:国際誌  

    組織学的に前立腺導内管癌(IDC-P)が認められた、前立腺神経内分泌癌(NEPC)発症の3症例について報告した。症例1は76歳男性で、アンドロゲン除去療法(ADT)開始から8年後に前立腺特異抗原が高値であったため再生検を行ったところ、NEPCであることが確認された。症例2は70歳男性で、ADT開始から3年後に多発性骨転移が認められ、その際に神経特異性エノラーゼの増加に伴い、NEPCが認められた。症例3は70歳男性で、初回の経尿道的切除標本の組織学的検査により、NEPCと確定診断された。また、NEPCの組織学的所見では、3症例ともに神経内分泌癌と腺房腺癌が多様な比率で混合して観察され、神経内分泌癌の構成成分ではシナプトフィジンとクロモグラニンAに陽性で、腺癌構成成分ではPSAとNKX3.1に陽性が認められた。さらに、3例の初回に行われたHE染色スライドを調べたところ、全3例からIDC-Pが検出され、過去に当院で前立腺生検を行い、初期生検標本が得られたNEPC患者全6例からも、IDC-P構成成分が同様に検出されていたことが確認された。本例により、前立腺初期の組織学的標本によるIDC-Pの検出から、NEPCへの形質転換が予測可能であることが示唆された。

  • PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8 査読

    Ikeda J, Ohe C, Yoshida T, Ohsugi H, Sugi M, Tsuta K, Kinoshita H

    Anticancer research   41 ( 9 )   4577 - 4586   2021年09月( ISSN:0250-7005

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.21873/anticanres.15271

    PubMed

  • Photodynamic Diagnosis–guided Dual Laser Ablation for Upper Urinary Tract Carcinoma: Preoperative Preparation, Surgical Technique, and Clinical Outcomes 査読

    YoshidaT, Murota T, Matsuzaki T, Nakao K, Ohe C, Matsuda T, Kinoshita H

    European urology Open science   28   17 - 25   2021年06月( ISSN:0302-2838

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1016/j.euros.2021.03.009

  • 【治療方針を変える病理所見 診療ガイドラインと治療戦略】(第1部)臓器別 腎

    大江 知里, 吉田 崇, 大杉 治之, 黒田 直人, 長嶋 洋治

    病理と臨床   39 ( 臨増 )   156 - 162   2021年04月( ISSN:0287-3745

     詳細を見る

    担当区分:筆頭著者  

  • Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer 査読

    Ikeda J, Ohe C, Yoshida T, Kuroda N, Saito R, Kinoshita H, Tsuta K, Matsuda T

    Pathol Int.   71 ( 3 )   173 - 182   2021年03月

     詳細を見る

    担当区分:責任著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1111/pin.13060

    PubMed

  • Signet-ring cell/histiocytoid carcinoma in the axilla: A case report with genetic analysis using next-generation sequencing

    Ito Y, Ishida M, Ohe C, Miyasaka C, Tsuta K.

    Journal of cutaneous pathology   48 ( 1 )   102 - 105   2021年01月( ISSN:0303-6987

     詳細を見る

    国際・国内誌:国際誌  

    DOI: 10.1111/cup.13838

  • Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas 査読

    Furuya M, Iribe Y, Nagashima Y, Kambe N, Ohe C, Kinoshita H, Sato C, Kishida T, Okubo Y, Numakura K, Nanjo H, Nakaigawa N, Makiyama K, Hasumi H, Iwashita H, Ohta J, Kitamura H, Nakajima T, Yoshida T, Nakagawa M, Tanaka R, Yao M

    Journal of clinical pathology   73 ( 12 )   819 - 825   2020年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1136/jclinpath-2020-206548

    PubMed

  • The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma 査読

    Ohsugi H, Yoshida T, Ohe C, Ikeda J, Sugi M, Kinoshita H, Tsuta K, Matsuda T

    Annals of surgical oncology   28 ( 4 )   2359 - 2366   2020年09月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1245/s10434-020-09075-4

    PubMed

  • Robot-assisted laparoscopic vesicule prostatectomy for mixed epithelial–stromal tumor of seminal vesicle 査読

    Yuki Masuo, Hisanori Taniguchi, Tomoaki Matsuzaki, Hidefumi Kinoshita1 Chika Miyasaka, Chisato Ohe and Tadashi Matsuda

    IJU Case Reports   3 ( 3 )   103 - 107   2020年04月( ISSN:2577-171X

     詳細を見る

    国際・国内誌:国際誌  

    DOI: 10.1002/iju5.12157

  • Clinical impact of segmental renal vein invasion on recurrence in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 査読

    Yoshida T, Ohe C, Tsuzuki T, Sugi M, Kinoshita H, Tsuta K, Matsuda T

    International journal of clinical oncology   25 ( 3 )   464 - 471   2020年03月( ISSN:1341-9625

     詳細を見る

    担当区分:責任著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国内誌  

    DOI: 10.1007/s10147-019-01543-6.

    PubMed

  • Classification of solid renal tumor with oncocytic/eosinophilic cytoplasm: is hybrid oncocytic/chromophobe renal tumor a subtype of oncocytoma, chromophobe renal cell carcinoma, or a distinct tumor entity? 招待

    Mikami S, Kuroda N, Nagashima Y, Ohe C, Hayashi H, Mizuno R, Oya M, Kameyama K

    Annals of translational medicine   7 ( Suppl 8 )   S350   2019年12月

     詳細を見る

    国際・国内誌:国際誌  

    DOI: 10.21037/atm.2019.09.77

    PubMed

  • Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. 査読

    Ohashi R, Martignoni G, Hartmann A, Caliò A, Segala D, Stöhr C, Wach S, Erlmeier F, Weichert W, Autenrieth M, Schraml P, Rupp NJ, Ohe C, Otsuki Y, Kawasaki T, Kobayashi H, Kobayashi K, Miyazaki T, Shibuya H, Usuda H, Umezu H, Fujishima F, Furusato B, Osakabe M, Sugai T, Kuroda N, Tsuzuki T, Nagashima Y, Ajioka Y, Moch H

    Virchows Archiv : an international journal of pathology   476 ( 3 )   409 - 418   2019年11月( ISSN:0945-6317

     詳細を見る

  • Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses Than Seen in the Eosinophilic Subtype. 査読

    Ohashi R, Schraml P, Angori S, Batavia AA, Rupp NJ, Ohe C, Otsuki Y, Kawasaki T, Kobayashi H, Kobayashi K, Miyazaki T, Shibuya H, Usuda H, Umezu H, Fujishima F, Furusato B, Osakabe M, Sugai T, Kuroda N, Tsuzuki T, Nagashima Y, Ajioka Y, Moch H

    Cancers   11 ( 10 )   1492 - 1492   2019年10月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    DOI: 10.3390/cancers11101492

    PubMed

  • Hereditary leiomyomatosis and renal cell cancer syndrome in which skin biopsy enabled diagnosis.

    Matsuda T, Kambe N, Ly NTM, Ueda-Hayakawa I, Yamazaki F, Ohe C, Yoshida K, Kinoshita H, Furuya M, Okamoto H

    The Journal of dermatology   46 ( 8 )   e285 - e287   2019年08月( ISSN:0385-2407

     詳細を見る

    国際・国内誌:国際誌  

    DOI: 10.1111/papr.12782

    PubMed

  • Histological Validation of 11Carbon-Acetate Positron Emission Tomography/Computerized Tomography in Detecting Lymph Node Metastases in Prostate Cancer. 査読

    Rajarubendra N, Almeida F, Manojlovic Z, Ohe C, Ahmadi N, Cacciamani G, Qiu M, Abreu A, Cai J, Miranda G, Stern MC, Carpten J, Kuhn P, Amin MB, Gill PS, Aron M, Gill IS.

    Journal of Urology   201 ( 2 )   332 - 341   2019年02月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

  • Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer? 査読

    Oishi M, Shin T, Ohe C, Nassiri N, Palmer SL, Aron M, Ashrafi AN, Cacciamani GE, Chen F, Duddalwar V, Stern MC, Ukimura O, Gill IS, Luis de Castro Abreu A

    Journal of Urology   201 ( 2 )   268 - 277   2019年02月( ISSN:0022-5347

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.juro.2018.08.046

  • Penile warty mucoepidermoid carcinoma with features of stratified mucin-producing intra-epithelial lesion and invasive stratified mucin-producing carcinoma

    Kenji Yorita, Naoto Kuroda, Takushi Naroda, Masato Tamura, Chisato Ohe, Mukul Divatia, Mahul B Amin, Antonio L Cubilla, Dimitry V Kazakov, Ondrej Hes, Michael Michal, Michal Michal

    Histopathology   72 ( 5 )   867 - 873   2018年04月( ISSN:1365-2559

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Aims: Stratified mucin-producing intra-epithelial lesion (SMILE) and invasive stratified mucin-producing carcinoma (ISMC) are recently described cervical and penile lesions. We report an unusual case of mixed variant of penile squamous cell carcinomas with warty, usual and mucoepidermoid SMILE/ISMC features. Methods and results: A 62-year-old Japanese man had a glans penis lesion of one-and-a-half years’ duration, suggesting malignancy. Partial penectomy and left inguinal lymphadenectomy were performed. Pathological evaluation revealed a mixed squamous cell carcinoma with warty, mucinous and usual features. The mucinous component resembled mucoepidermoid carcinoma (MEC) and SMILE/ISMC. Glandular differentiation was absent. All the diverse tumour components were negative for p16, which was confirmed by negative human papillomavirus (HPV) genotyping. The mucinous component was diffusely positive for cytokeratin 7 and largely negative for cytokeratin 5 and p63. Fluorescence in-situ hybridisation did not detect rearrangement in the MAML2 or EWSR1 genes. The tumour was pathological stage pT2, pN1 (AJCC prognostic stage group IIIA) and was disease-free 26 months after surgery. Conclusions: The lack of glands in the mucinous areas suggested that MEC should be separated from adenosquamous carcinoma (ASC). Penile SMILE/ISMC may occur without dependence upon HPV status. Further studies will be necessary to determine the pathogenesis and definition of penile SMILE/ISMC, the presence of true MEC arising from the glans penis and the clinicopathological differences of penile ASC, MEC and SMILE/ISMC. Herein, we refer to the SMILE-like penile lesion as ‘mucinous penile intra-epithelial neoplasia’.

    DOI: 10.1111/his.13438

  • Tubular adenomas with clear cell change in the colorectum: A case with four lesions and a review of the literature

    Chika Miyasaka, Mitsuaki Ishida, Chisato Ohe, Yoshiko Uemura, Yugo Ando, Toshiro Fukui, Koji Tsuta

    Pathology International   68 ( 4 )   256 - 258   2018年04月( ISSN:1440-1827

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/pin.12628

    PubMed

  • Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. 査読

    Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, Agaimy A, Amin MB, Argani P, Chen YB, Cheng L, Colecchia M, Compérat E, Werneck da Cunha I, Epstein JI, Gill AJ, Hes O, Hirsch MS, Jochum W, Kunju LP, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Nesi G, Osunkoya AO, Picken MM, Rao P, Reuter VE, de Oliveira Salles PG, Schultz L, Tickoo SK, Tomlins SA, Trpkov K, Amin MB.

    Am J Surg Pathol   42 ( 3 )   279 - 292   2018年03月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   国際・国内誌:国際誌  

  • Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI/ultrasonography image-fusion targeted biopsy of the prostate 査読

    Toshitaka Shin, Thomas B. Smyth, Osamu Ukimura, Nariman Ahmadi, Andre Luis de Castro Abreu, Chisato Ohe, Masakatsu Oishi, Hiromitsu Mimata, Inderbir S. Gill

    BJU International   121 ( 1 )   77 - 83   2018年01月( ISSN:1464-410X

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Objective: To evaluate the accuracy of a magnetic resonance imaging (MRI)-based Likert scoring system in the detection of clinically significant prostate cancer (CSPC), using MRI/ultrasonography (US) image-fusion targeted biopsy (FTB) as a reference standard. Patients and Methods: We retrospectively reviewed 1218 MRI-detected lesions in 629 patients who underwent subsequent MRI/US FTB between October 2012 and August 2015. 3-Tesla MRI was independently reported by one of eight radiologists with varying levels of experience and scored on a five-point Likert scale. All lesions with Likert scores 1–5 were prospectively defined as targets for MRI/US FTB. CSPC was defined as Gleason score ≥7. Results: The median patient age was 64 years, PSA level 6.97 ng/mL and estimated prostate volume 52.2 mL. Of 1218 lesions, 48% (n = 581) were rated as Likert 1–2, 35% (n = 428) were Likert 3 and 17% (n = 209) were Likert 4–5. For Likert scores 1–5, the overall cancer detection rates were 12%, 13%, 22%, 50% and 59%, respectively, and the CSPC detection rates were 4%, 4%, 12%, 33% and 48%, respectively. Grading using the five-point scale showed strong positive correlation with overall cancer detection rate (r = 0.949, P = 0.05) and CSPC detection rate (r = 0.944, P = 0.05). By comparison, in Likert 4–5 lesions, significant differences were noted in overall cancer detection rate (63% vs 35%
    P = 0.001) and CSPC detection rate (47% vs 29%
    P = 0.027) for the more experienced vs the less experienced radiologists. Conclusions: The detection rates of overall cancer and CSPC strongly correlated with the five-point grading of the Likert scale. Among radiologists with different levels of experience, there were significant differences in these cancer detection rates.

    DOI: 10.1111/bju.13972

    PubMed

  • Thymic enteric type adenocarcinoma: A case report with cytological features 査読

    Marie Tamai, Mitsuaki Ishida, Yusuke Ebisu, Hisashi Okamoto, Chika Miyasaka, Chisato Ohe, Yoshiko Uemura, Tomohito Saito, Tomohiro Murakawa, Koji Tsuta

    DIAGNOSTIC CYTOPATHOLOGY   46 ( 1 )   92 - 97   2018年01月( ISSN:8755-1039

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Primary thymic adenocarcinoma is an extremely rare tumor, and thymic enteric type adenocarcinoma has recently been proposed as a distinct pathological entity. Herein, we report the first cytological description of thymic enteric type adenocarcinoma. A 29-year-old Japanese female without a significant past medical history was found to have an abnormal chest shadow. Chest computed tomography demonstrated a well-circumscribed tumor in the anterior mediastinum, and thymectomy was performed. The Papanicolaou staining of the touch smear of the resected tumor demonstrated tightly cohesive epithelial cell clusters in a necrotic background. These cells were cuboidal to columnar in shape and had large round to oval nuclei with conspicuous nucleoli. Some of these neoplastic cells had intracytoplasmic mucin. Immunocytochemically, the neoplastic cells were positive for cytokeratin 20 and CDX-2. Histopathological study revealed tubular and papillotubular neoplastic growth composed of cuboidal to columnar neoplastic cells that contained large round to oval nuclei. Some of the neoplastic cells had intracytoplasmic mucin. Immunohistochemical study confirmed the expression of cytokeratin 20 and CDX-2. The final diagnosis of thymic enteric type adenocarcinoma was made. The cytological and immunocytochemical features of this case led to a diagnosis of enteric type adenocarcinoma. However, these features alone cannot be differentiated from a metastatic adenocarcinoma arising from the gastrointestinal tract. Cytological examination of a fine-needle aspiration of the mediastinal tumor has been reported to be useful in making a diagnosis. Therefore, an awareness of this new pathological entity is important for differentiating a thymic tumor from a metastatic carcinoma in the thymus.

    DOI: 10.1002/dc.23806

    PubMed

  • A novel machine learning approach reveals latent vascular phenotypes predictive of renal cancer outcome 査読

    Nathan Ing, Fangjin Huang, Andrew Conley, Sungyong You, Zhaoxuan Ma, Sergey Klimov, Chisato Ohe, Xiaopu Yuan, Mahul B. Amin, Robert Figlin, Arkadiusz Gertych, Beatrice S. Knudsen

    SCIENTIFIC REPORTS   7 ( 1 )   13190   2017年10月( ISSN:2045-2322

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Gene expression signatures are commonly used as predictive biomarkers, but do not capture structural features within the tissue architecture. Here we apply a 2-step machine learning framework for quantitative imaging of tumor vasculature to derive a spatially informed, prognostic gene signature. The trained algorithms classify endothelial cells and generate a vascular area mask (VAM) in H&E micrographs of clear cell renal cell carcinoma (ccRCC) cases from The Cancer Genome Atlas (TCGA). Quantification of VAMs led to the discovery of 9 vascular features (9VF) that predicted disease-free-survival in a discovery cohort (n = 64, HR = 2.3). Correlation analysis and information gain identified a 14 gene expression signature related to the 9VF's. Two generalized linear models with elastic net regularization (14VF and 14GT), based on the 14 genes, separated independent cohorts of up to 301 cases into good and poor disease-free survival groups (14VF HR = 2.4, 14GT HR = 3.33). For the first time, we successfully applied digital image analysis and targeted machine learning to develop prognostic, morphology-based, gene expression signatures from the vascular architecture. This novel morphogenomic approach has the potential to improve previous methods for biomarker development.

    DOI: 10.1038/s41598-017-13196-4

  • Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma 査読

    Deepika Sirohi, Steven C. Smith, Chisato Ohe, Piergiuseppe Colombo, Mukul Divatia, Ema Dragoescu, Priya Rao, Michelle S. Hirsch, Ying-Bei Chen, Rohit Mehra, Mahul B. Amin

    HUMAN PATHOLOGY   67   134 - 145   2017年09月( ISSN:0046-8177

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Renal medullary carcinoma (RMC) is a highly aggressive renal cell carcinoma arising in the collecting system and requiring careful correlation with status of sickle cell trait. A panel of international experts has recently proposed provisional diagnostic terminology, renal cell carcinoma, unclassified, with medullary phenotype, based on encountering an extraordinarily rare tumor with RMC morphology and immunophenotype in an individual proven not to have a hemoglobinopathy. Herein, we extend this observation to a cohort of 5 such tumors, morphologically similar to RMC, lacking SMARCB1 expression by immunohistochemistry, but each without evidence of a hemoglobinopathy. The tumors arose in 4 men and 1 woman with a mean age of 44 years, occurring in 3 left and 2 right kidneys. Clinically, aggression was apparent with involvement of perinephric adipose tissue in all 5 cases, nodal metastasis in 4 of 5 cases, and death of disease in 4 of 5 cases within 3-27 months. Histologic sections showed poorly differentiated adenocarcinoma, often with solid and nested growth patterns, as well as infiltrative glandular, tubulopapillary, cribriform, or reticular growth. Rhabdoid and sarcomatoid cytomorphology was seen in a subset. All tumors showed PAX8 nuclear positivity and SMARCB1 loss, with OCT3/4 expression in 4 of 5 cases. In summary, this first series of renal cell carcinoma, unclassified, with medullary phenotype documents tumors with morphologic, immunophenotypic, and prognostic features of RMC occurring in individuals without sickle cell trait. Although greater biologic and molecular understanding is needed, the available evidence points to these cases representing a sporadic counterpart to sickle cell trait-associated RMC. (C) 2017 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.humpath.2017.07.006

    PubMed

  • A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma 査読

    Steven C. Smith, Deepika Sirohi, Chisato Ohe, Jonathan B. McHugh, Jason L. Hornick, Jigna Kalariya, Sushil Karia, Katie Snape, Shirley V. Hodgson, Andi K. Cani, Daniel Hovelson, Daniel J. Luthringer, Guido Martignoni, Ying-Bei Chen, Scott A. Tomlins, Rohit Mehra, Mahul B. Amin

    HISTOPATHOLOGY   71 ( 1 )   42 - 52   2017年07月( ISSN:0309-0167

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Aims: Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a high-grade, aggressive tubulopapillary carcinoma, arising predominantly in the setting of the hereditary leiomyomatosis-RCC syndrome of familial uterocutaneous leiomyomatosis and deficiency of FH. In contrast, succinate dehydrogenase (SDH)-deficient RCC is a lower-grade oncocytic carcinoma with cytoplasmic flocculence/vacuolation and inclusions, arising mostly in individuals harbouring germline mutations of subunit B of the SDH complex (SDHB). Herein we aim to report the clinicopathologic features of a novel form of FH-deficient RCC showing a low grade oncocytic morphology, reminiscent of SDH-deficient RCC.
    Methods and results: These distinctive, low-grade oncocytic neoplasms, with solid, nested and focally tubular architecture (2-90 mm), arose in four males (aged 11-41 years). Uniform cytology of polygonal cells, with flocculent, vacuolated eosinophilic cytoplasm with scattered inclusions, fine chromatin, and inconspicuous nucleoli, was apparent. Despite these features suggestive of SDH-deficient RCC, each tumour was confirmed as an FH-deficient carcinoma with retained SDHB expression. One case showed a synchronous, anatomically separate, typical highgrade FH-deficient RCC; one other showed such a tumour at nephrectomy 4 years later. No progression has been noted at 3 and 7 years in the cases with only the SDH-like lesions; the two cases with separate, typical FH-deficient RCCs progressed.
    Conclusions: In summary, we characterize a novel oncocytic type of FH-deficient RCC with a striking resemblance to SDH-deficient RCC, posing a diagnostic challenge and raising concerns about sampling and multifocality for syndrome-associated cases under surveillance protocols.

    DOI: 10.1111/his.13183

  • Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy 査読

    Sohei Satoi, Hiroaki Yanagimoto, Tomohisa Yamamoto, Chisato Ohe, Chika Miyasaka, Yoshiko Uemura, Satoshi Hirooka, So Yamaki, Hironori Ryota, Taku Michiura, Kentaro Inoue, Yoichi Matsui, Noboru Tanigawa, Masanori Kon

    SURGERY TODAY   47 ( 1 )   84 - 91   2017年01月( ISSN:0941-1291

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    We compared the clinical outcomes of pancreatic ductal adenocarcinoma (PDAC) resection after neoadjuvant chemoradiation therapy (NACRT) vs. chemotherapy (NAC).
    The study population comprised 81 patients with UICC stage T3/4 PDAC, treated initially by NACRT with S-1 in 40 and by NAC with gemcitabine + S-1 in 41. This was followed by pancreatectomy with routine nerve plexus resection in 35 of the patients who had received NACRT and 32 of those who had received NAC. We compared the survival curves and clinical outcomes of these two groups.
    The rates of clinical response, surgical resectability, and margin-negative resection were similar. The NACRT group patients had significantly higher rates of Evans stage &gt;= IIB tumors (29 vs. 0 %, respectively, p = 0.010) and negative lymph nodes (49 vs. 16 %, respectively, p = 0.021) than the NAC group patients. There was no difference in disease-free survival between the groups, but the disease-specific survival of the NAC group patients was better than that of the NACRT group patients (p = 0.034). Patients undergoing pancreatectomy with nerve plexus resection following NACRT had significantly higher rates of intractable diarrhea and ascites but consequently received significantly less adjuvant chemotherapy and therapeutic chemotherapy for relapse.
    NACRT followed by pancreatectomy with nerve plexus resection is superior for achieving local control, but postoperative diarrhea and ascites may prohibit continuation of adjuvant chemotherapy or chemotherapy for relapse (UMIN4148).

    DOI: 10.1007/s00595-016-1358-9

  • Sclerosing Esophagitis with IgG4-positive Plasma Cell Infiltration 査読

    Shigeo Mori, Yoshiya Tahashi, Kazushige Uchida, Tsukasa Ikeura, Naoyuki Danbara, Takahiro Wakamatsu, Takeo Kusuda, Yu Takahashi, Masato Yanagawa, Mitsunobu Matsushita, Chisato Ohe, Taku Michiura, Kentaro Inoue, Masanori Kon, Kazuichi Okazaki

    INTERNAL MEDICINE   56 ( 22 )   3023 - 3026   2017年( ISSN:0918-2918

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    The patient was a 76-year-old woman who had noticed slight difficulty in swallowing in the 3 years prior to this presentation. Her dysphagia progressed while she was hospitalized following cervical cancer surgery. Esophagogastroduodenoscopy and an esophagram showed circumferential erosion and a stricture of the thoracic esophagus. Esophageal resection was performed; the resected specimens showed a stricture and wall thickening. Histologically, transmural hyperplasia, which consisted of inflammatory granulation tissue with the abundant infiltration of IgG4-positive plasma cells and lymphocytes, was observed. The patient was diagnosed with probable IgG4-related disease. IgG4-related esophageal disease presenting as esophageal lesions alone is a very rare condition.

    DOI: 10.2169/internalmedicine.8095-16

    PubMed

  • Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma 査読

    Steven C. Smith, Kiril Trpkov, Ying-Bei Chen, Rohit Mehra, Deepika Sirohi, Chisato Ohe, Andi K. Cani, Daniel H. Hovelson, Kei Omata, Jonathan B. McHugh, Wolfram Jochum, Maurizio Colecchia, Mitual Amin, Mukul K. Divatia, Ondrej Hes, Santosh Menon, Isabela Werneck da Cunha, Sergio Tripodi, Fadi Brimo, Anthony J. Gill, Adeboye O. Osunkoya, Cristina Magi-Galluzzi, Mathilde Sibony, Sean R. Williamson, Gabriella Nesi, Maria M. Picken, Fiona Maclean, Abbas Agaimy, Liang Cheng, Jonathan I. Epstein, Victor E. Reuter, Satish K. Tickoo, Scott A. Tomlins, Mahul B. Amin

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   40 ( 11 )   1457 - 1472   2016年11月( ISSN:0147-5185

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    An emerging group of high-grade renal cell carcinomas (RCCs), particularly carcinomas arising in the hereditary leiomyomatosis renal cell carcinoma syndrome (HLRCC), show fumarate hydratase (FH) gene mutation and loss of function. On the basis of similar cytomorphology and clinicopathologic features between these tumors and cases described as tubulocystic carcinomas with poorly differentiated foci (TC-PD) of infiltrative adenocarcinoma, we hypothesized a relationship be-tween these entities. First, 29 RCCs with morphology of TC-PD were identified retrospectively and assessed for FH expression and aberrant succination (2SC) by immunohistochemistry (IHC), with targeted next-generation sequencing of 409 genes-including FH-performed on a subset. The 29 TC-PD RCCs included 21 males and 8 females, aged 16 to 86 years (median, 46), with tumors measuring 3 to 21 cm (median, 9) arising in the right (n = 16) and left (n = 13) kidneys. Family history or stigmata of HLRCC were identifiable only retrospectively in 3 (12%). These tumors were aggressive, with 79% showing perinephric extension, nodal involvement in 41%, and metastasis in 86%. Of these, 16 (55%) demonstrated loss of FH by IHC (14/14 with positive 2SC). In contrast, 5 (17%) showed a wild-type immunoprofile of FH+/2SC-. An intriguing group of 8 (28%) showed variable FH+ positivity, but with strong/diffuse 2SC+. Next-generation sequencing revealed 8 cases with FH mutations, including 5 FH-/2SC+ and 3 FH-/2SC+ cases, but none in FH+/2SC- cases. Secondly, we retrospectively reviewed the morphology of 2 well-characterized cohorts of RCCs with FH-deficiency determined by IHC or sequencing (n = 23 and n = 9), unselected for TC-PD pattern, identifying the TC-PD morphology in 10 (31%). We conclude that RCCs with TC-PD morphology are enriched for FH deficiency, and we recommend additional workup, including referral to genetic counseling, for prospective cases. In addition, based on these and other observations, we propose the term "FH-deficient RCC" as a provisional term for tumors with a combination of suggestive morphology and immunopheno-type but where genetic confirmation is unavailable upon diagnosis. This term will serve as a provisional nomenclature that will enable triage of individual cases for genetic counseling and testing, while designating these cases for prospective studies of their relationship to HLRCC.

  • The role of CD5 expression in thymic carcinoma: possible mechanism for interaction with CD5(+) lymphoid stroma (microenvironment) 査読

    Naoki Hosaka, Chisato Ohe, Chika Miyasaka, Yorika Nakano, Noriko Sakaida, Yoshiko Uemura, Yukihito Saito, Susumu Ikehara, Airo Tsubura, Hakuo Takahashi

    HISTOPATHOLOGY   68 ( 3 )   450 - 455   2016年02月( ISSN:0309-0167

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    AimsMost thymic carcinomas express the lymphocyte marker CD5 aberrantly. This study was performed to examine the role of the self-reactive CD5 antigen in thymic carcinoma.
    Methods and resultsWe examined CD5 expression in thymic carcinoma in relation to the lymphoid stroma. All cases of thymic carcinoma examined expressed CD5. A number of CD5(+) lymphocytes were also present in the stroma of thymic carcinoma. The CD5(+) tumour areas were predominantly in contact with the lymphoid stroma, and the expression level was significantly lower in tumour cells than lymphocytes. Although p53 and Bcl-2 expression levels were significantly higher in thymic carcinoma than normal thymic epithelial cells (TECs), they did not differ between CD5(+) and CD5(-) areas. E-cadherin expression in thymic carcinoma was comparable with that of normal TECs, and it also did not differ between these areas. In contrast, both Ki-67 index and mitotic activity were significantly higher in thymic carcinoma than normal TECs, and they were significantly higher in CD5(+) than CD5(-) areas.
    ConclusionsCD5 may be induced by interaction with CD5(+) lymphoid stroma, and may be related to tumour proliferation. CD5 induction may also be a significant and/or specific effect of the tumour microenvironment of the thymus.

    DOI: 10.1111/his.12742

  • Review of renal anastomosing hemangioma with focus on clinical and pathological aspects 査読

    Naoto Kuroda, Chisato Ohe, Sirohi Deepika, Kenji Yorita, Shuji Mikami, Mitsuko Furuya, Yoji Nagashima, Ondrej Hes, Abbas Agaimy, Michal Michal, Mahul B. Amin

    Polish Journal of Pathology   67 ( 2 )   97 - 101   2016年( ISSN:1233-9687

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Renal anastomosing hemangiomas (RAH) has been recently proposed as a new entity. In this article, we summarize the clinicopathologic features of this tumor. RAH usually develops on a background of end-stage renal disease. Macroscopically, tumors are well-defined and their cut surface shows mahogany brown spongy tissue with epicenter in the renal medulla. Tumors are usually small, but larger lesions are reported. On microscopic examination, the tumor consists of sinusoid-like vascular channels lined by cuboidal endothelial cells with occasional hobnail-like appearance of endothelial cells closely mimicking splenic sinusoids. Eosinophilic hyaline globules may be present in the cytoplasm of neoplastic endothelial cells. Extramedullary hematopoiesis containing erythroid precursor and megakaryocytes may be present in the vascular lumens. Immunohistochemically, endothelial cells are positive for CD31 and CD34, but negative for D2-40, GLUT-1 and HHV8. The surrounding stroma around endothelial cells demonstrates positivity for a smooth muscle action. To date, there are no studies on molecular genetic aspects of RAH. This tumor is indolent based on site and size of the lesion, partial or nephrectomy is sufficient as a therapeutic modality.

    DOI: 10.5114/pjp.2016.61443

    PubMed

  • Chromophobe renal cell carcinoma with neuroendocrine and neuroendocrine-like features. Morphologic, immunohistochemical, ultrastructural, and array comparative genomic hybridization analysis of 18 cases and review of the literature 査読

    Kvetoslava Peckova, Petr Martinek, Chisato Ohe, Naoto Kuroda, Stela Bulimbasic, Enric Condom Mundo, Delia Perez Montiel, Jose I. Lopez, Ondrej Daum, Pavia Rotterova, Bohuslava Kokoskova, Magdalena Dubova, Kristyna Pivovarcikova, Kevin Bauleth, Petr Grossmann, Milan Hora, Kristyna Kalusova, Whitney Davidson, David Slouka, Sulc Miroslav, Petr Buzrla, Mirka Hynek, Michal Michal, Ondrej Hes

    ANNALS OF DIAGNOSTIC PATHOLOGY   19 ( 4 )   261 - 268   2015年08月( ISSN:1092-9134

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Chromophobe renal cell carcinoma (CRCC) with neuroendocrine differentiation (CRCCND) has only recently been described. Eighteen cases of CRCC with morphologic features suggestive of neuroendocrine differentiation were selected from among 624 CRCCs in our registry. The tissues were fixed in neutral formalin, embedded in paraffin, cut into 4- to 5-mu m-thick sections, and stained with hematoxylin and eosin. As CRCC with neuroendocrine features, tumors with following morphology were suggested: (1) trabecular/palisading/ribbon-like, gyriform, insular, glandular, and solid pattern; (2) uniform polygonal cells formed in small islets; and (3) cribriform pattern in combination with palisading. Selected cases were further analyzed using immunohistochemistry, electron microscopy, array comparative genomic hybridization, and fluorescence in situ hybridization. Cases were classified as CRCCND or CRCC with neuroendocrine-like features (CRCCND-L) based on the immunohistochemical expression of neuroendocrine markers: CRCCND, 4 cases, age range 49 to 79 years, size ranged from 2.2 to 22 cm, and CRCCND-L, 14 cases, age range 34 to 74 years, size range 3.8 to 16.5 cm. Follow-up information was available for 11 of 18 patients aged 0.5 to 12 years. Two of 4 CRCCNDs showed aggressive clinical course with metastatic spreading. Chromophobe renal cell carcinomas with neuroendocrine differentiation were focally positive for CD56 (4/4), synaptophysin (4/4), chromogranin A (1/4), and neuron-specific enolase (3/4). All 14 CRCCND-Ls were mostly negative or very weakly focally positive for some of the aforementioned markers. All 18 tumors were positive for cytokeratin 7 and CD117. Ultrastructural analysis showed poorly preserved neuroendocrine granules only in 2 of 4 analyzed CRCCNDs. Losses of chromosomes 1, 2, 6, and 10 were found in all analyzable CRCCNDs, whereas multiple losses (chromosomes 1, 2, 6, 10, 13, 17, and 21) and gains (chromosomes 4, 11, 12, 14, 15, 16, 19, and 20) were found in CRCCND-L. (c) 2015 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.anndiagpath.2015.05.001

  • Fluorescence cytology with 5-aminolevulinic acid in EUS-guided FNA as a method for differentiating between malignant and benign lesions 査読

    Tsukasa Ikeura, Makoto Takaoka, Kazushige Uchida, Masaaki Shimatani, Hideaki Miyoshi, Kota Kato, Chisato Ohe, Yoshiko Uemura, Masaki Kaibori, A-Hon Kwon, Kazuichi Okazaki

    GASTROINTESTINAL ENDOSCOPY   81 ( 6 )   1457 - 1462   2015年06月( ISSN:0016-5107

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Background: EUS-guided FNA (EUS-FNA) has been increasingly performed to obtain specimens for the pathological evaluation of patients with GI and pancreaticobiliary masses as well as lymphadenopathies of unknown origin. Photodynamic diagnosis by using 5-aminolebulinic acid (ALA) has been reported to be useful for enabling the visual differentiation between malignant and normal tissue in various cancers.
    Objective: To evaluate the diagnostic accuracy of fluorescence cytology with ALA in EUS-FNA.
    Design: A prospective study.
    Setting: A single center.
    Patients: A total of 28 consecutive patients who underwent EUS-FNA for the pathological diagnosis of a pancreaticobiliary mass lesion or intra-abdominal lymphadenopathy of unknown origin.
    Interventions: Patients were orally administered ALA 3 to 6 hours before EUS-FNA. The sample was obtained via EUS-FNA for fluorescence cytology and conventional cytology. A single gastroenterologist performed the fluorescence cytology by using fluorescence microscopy after the procedure, independently of the conventional cytology by pathologists.
    Main Outcome Measurements: The accuracy of fluorescence cytology with ALA in the differentiation between benign and malignant lesions by comparing the results of fluorescence cytology with the final diagnosis.
    Results: Of the 28 patients included in the study, 22 were considered as having malignant lesions and 6 patients as having benign lesions. Fluorescence cytology could correctly discriminate between benign and malignant lesions in all patients. Therefore, both the sensitivity and specificity of fluorescence cytology were 100% in our study.
    Limitations: Fluorescence cytology was performed by only 1 gastroenterologist with a small number of patients.
    Conclusion: Fluorescence cytology with ALA in EUS-FNA may be an effective and simple method for differentiating between benign and malignant lesions.

    DOI: 10.1016/j.gie.2015.01.031

  • A Fatal Case of Infantile Malignant Osteopetrosis Complicated by Pulmonary Arterial Hypertension after Hematopoietic Stem Cell Transplantation 査読

    Yuichi Kuroyanagi, Hirohide Kawasaki, Yukihiro Noda, Taichi Ohmachi, Shin-ichiro Sekiya, Ken Yoshimura, Chisato Ohe, Toshimi Michigami, Keiichi Ozono, Kazunari Kaneko

    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE   234 ( 4 )   309 - 312   2014年12月( ISSN:0040-8727

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Infantile malignant osteopetrosis (IMO) is a rare and fatal autosomal recessive condition characterized by a generalized increased in bone density. Hematopoietic stem cell transplantation (HSCT) is the only effective and rational therapy with achieving long-term disease-free survival. However, complications with HSCT for IMO remain unclear. Here we describe a male infant with IMO, carrying two novel mutations in the T-cell immune regulator 1 (TCIRG1) gene. The TCIRG1 gene encodes the a3 subunit of vacuolar H+-ATPase that plays an essential role in the resorptive function of osteoclasts. Direct sequencing of all 20 exons of the TCIRG1 gene revealed a single nucleotide change in exon 11 (c1305 G &gt; T), which causes the substitution of Asp (GAT) for Glu (GAG) at position 435, and a two-nucleotide deletion in exon 16 (c19521953 del CA), causing a frame-shift mutation. However, the functional consequence of each mutation remains to be determined. Allogeneic HSCT was performed in the patient at the age of nine months. Donor engraftment was achieved, and abnormal bone metabolism and extramedullary hematopoiesis were corrected. Graft-versus-host disease was mild (grade I). However, the patient died of complication of pulmonary arterial hypertension at seven months after the HSCT. Postmortem examination revealed prominent vascular wall thickening of the pulmonary artery and macrophage infiltration to alveoli. It should be noted that a patient with IMO has a risk for pulmonary arterial hypertension, and the evaluation of pulmonary arterial flow should be included in the assessment of each patient with IMO even after HSCT.

    DOI: 10.1620/tjem.234.309

  • Pathological outcomes of Japanese men eligible for active surveillance after radical prostatectomy 査読

    Takahiro Inoue, Hidefumi Kinoshita, Hidekazu Inui, Yoshihiro Komai, Masayuki Nakagawa, Naoki Oguchi, Gen Kawa, Motohiko Sugi, Chisato Ohe, Chika Miyasaka, Yorika Nakano, Noriko Sakaida, Yoshiko Uemura, Tadashi Matsuda

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   19 ( 2 )   379 - 383   2014年04月( ISSN:1341-9625

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    The aim of this study was to analyze the pathological features of prostatectomy specimens from patients with low-risk prostate cancer eligible for active surveillance (AS) and evaluate preoperative data suitable for predicting upstaged (a parts per thousand yenpT3) or upgraded disease (Gleason score of a parts per thousand yen7), defined as 'reclassification'.
    A retrospective analysis of 521 consecutive radical prostatectomy procedures (January 2005 through to December 2011) performed at our institution without neoadjuvant hormonal therapy was performed. Eighty-four patients fulfilled the following criteria-clinical T1 or T2 disease, prostate-specific antigen (PSA) level of a parts per thousand currency sign10 ng/ml, one or two positive biopsies, and Gleason score of &lt; 7. Clinicopathological features at diagnosis were compared between patients with and without reclassification after radical prostatectomy.
    Forty of 84 patients (47.6 %) had a Gleason score of a parts per thousand yen7, and 8 (9.5 %) had upstaged disease (a parts per thousand yenpT3). Seven patients with upstaged disease also showed upgraded reclassification. Two patients with reclassification showed biochemical recurrence at 59 and 89 months after surgery, respectively. Preoperative parameters evaluated included age, PSA level, PSA density (PSAD), clinical T stage, and number and percentage of positive prostate cores. Among 82 patients with complete data, univariate analysis showed that PSAD (ng/ml(2)) was a significant parameter to discriminate patients with reclassified disease and those without reclassified disease (p &lt; 0.001). Multivariate analysis revealed that PSAD was the only independent variable to predict disease with reclassification (p = 0.006).
    Preoperative PSAD may be a good indicator for selecting patients eligible for AS in the Japanese population.

    DOI: 10.1007/s10147-013-0553-6

  • REVIEW OF SMALL CELL CARCINOMA OF THE KIDNEY WITH FOCUS ON CLINICAL AND PATHOBIOLOGICAL ASPECTS 査読

    Naoto Kuroda, Yoshiaki Imamura, Takeru Hamashima, Chisato Ohe, Shuji Mikami, Yoji Nagashima, Keiji Inoue, Delia Perez-Montiel, Predrik Petersson, Michal Michal, Ondrej Hes

    POLISH JOURNAL OF PATHOLOGY   65 ( 1 )   15 - 19   2014年03月( ISSN:1233-9687

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Small cell carcinoma (SmCC) of the kidney is extremely rare. In this article, we present a review of SmCC of the kidney with the focus on clinical and pathobiological aspects. Macroscopically, this tumor often shows a bulky mass extensively replacing the renal parenchyma with vascular invasion and metastasis to lymph nodes. Histologically, the tumor is composed of small cells with scant cytoplasm, round to oval nuclei, finely granular chromatin and inconspicuous nucleoli. Rosette or tubular formation may be present Immunohistochemically, neoplastic cells show variable positivity for neuron-specific enolase, chromogranin A, synaptophysin, CD57 (Leu7) and CD56. A dot-like staining pattern for cytokeratin may also be observed. An electron microscopic examination may identify electron-dense neurosecretory granules in the cytoplasm. As a therapeutic option, nephrectomy and systemic chemotherapy should be considered. However, despite multimodal therapy, most patients have a dismal outcome and die of widely metastatic disease within one to two years. As there are limited genetic data on SmCC of the kidney, a large series studying this will be needed in the future.

    DOI: 10.5114/PJP.2014.42664

  • Chromophobe renal cell carcinoma with neuroendocrine differentiation/morphology: A clinicopathological and genetic study of three cases 査読

    Chisato Ohe, Naoto Kuroda, Keiko Matsuura, Tomoki Kai, Masatsugu Moriyama, Shun Sugiguchi, Shintaro Terahata, Naoki Hosaka, Ondrej Hes, Michal Michal, Tadashi Matsuda, Yoshiko Uemura

    Human Pathology: Case Reports   1 ( 3 )   31 - 39   2014年( ISSN:2214-3300

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)  

    Chromophobe renal cell carcinoma (ChRCC) with neuroendocrine differentiation/ morphology (NED/NEM) is exceedingly rare. We present three cases of ChRCC with NED/NEM, two of which showed positivity for neuroendocrine markers on immunohistochemical analysis. Patients ranged in age from 49 to 79 years (mean: 64.3 years). One of the three patients died of metastatic disease to multiple organs. Of the remaining two patients, one is currently alive without disease and the other is alive with disease. Histologically, all three tumors were composed of conventional ChRCC and NEM showed glandular and rosette formation. Immunohistochemically, tumor cells were positive for CK7, KAI1, E-cadherin, and c-kit in both ChRCC and neuroendocrine areas in three cases. CD56 and synaptophysin immunoreactivity were detected in two cases
    in only the neuroendocrine area in one case and in both components in the other. Neuroendocrine granules were ultrastructurally observed at both neuroendocrine and conventional areas of ChRCC. Array comparative genomic hybridization (CGH) study indicated losses of chromosomes 1, 2, 6, 10, 17, 21, and Y in both conventional ChRCC and NED in one case. In addition, losses of chromosomes 1, 2, 4, 6, 9, 10, 13, 16p, 17, and 21 were observed in both components of the remaining one tumor. Furthermore, loss of chromosome 5 was identified only in the neuroendocrine area in this case. We concluded that the neuroendocrine area may reflect dedifferentiation within ChRCC. It is possible that losses of chromosomes 4, 5, and 16p may be involved in the neuroendocrine differentiation or progression of ChRCC.

    DOI: 10.1016/j.ehpc.2014.08.003

  • A renal epithelioid angiomyolipoma/perivascular epithelioid cell tumor with TFE3 gene break visualized by FISH 査読

    Chisato Ohe, Naoto Kuroda, Ondrej Hes, Michal Michal, Tomas Vanecek, Petr Grossmann, Yukichi Tanaka, Mio Tanaka, Hidekazu Inui, Yoshihiro Komai, Tadashi Matsuda, Yoshiko Uemura

    MEDICAL MOLECULAR MORPHOLOGY   45 ( 4 )   234 - 237   2012年12月( ISSN:1860-1480

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)  

    We present a case of renal epithelioid angiomyolipoma (eAML)/perivascular epithelioid cell tumor (PEComa) with a TFE3 gene break visible by fluorescence in situ hybridization (FISH). Histologically, the tumor was composed of mainly epithelioid cells forming solid arrangements with small foci of spindle cells. In a small portion of the tumor, neoplastic cells displayed nuclear pleomorphism, such as polygonal and enlarged vesicular nuclei with prominent nucleoli. Marked vascularity was noticeable in the background, and perivascular hyaline sclerosis was also seen. Immunohistochemically, neoplastic cells were diffusely positive for alpha-smooth muscle actin and melanosome in the cytoplasm. Nuclei of many neoplastic cells were positive for TFE3. FISH analysis of the TFE3 gene break using the Poseidon TFE3 (Xp11) Break probe revealed positive results. Reverse transcriptase-polymerase chain reactions (RT-PCR) for ASPL/TFE3, PRCC/TFE3, CLTC/TFE3, PSF/TFE3, and NonO/TFE3 gene fusions all revealed negative results. This is the first reported case of renal eAML/PEComa with a TFE3 gene break, and it has unique histological findings as compared to previously reported TFE3 gene fusion-positive PEComas. Pathologists should recognize that PEComa with TFE3 gene fusion can arise even in the kidney.

    DOI: 10.1007/s00795-012-0584-5

  • Utility of immunohistochemical analysis of KAI1, epithelial-specific antigen, and epithelial-related antigen for distinction of chromophobe renal cell carcinoma, an eosinophilic variant from renal oncocytoma 査読

    Chisato Ohe, Naoto Kuroda, Kosho Takasu, Hideto Senzaki, Nobuaki Shikata, Tadanori Yamaguchi, Chika Miyasaka, Yorika Nakano, Noriko Sakaida, Yoshiko Uemura

    MEDICAL MOLECULAR MORPHOLOGY   45 ( 2 )   98 - 104   2012年06月( ISSN:1860-1480

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)  

    Distinction of renal oncocytoma (RO) from chromophobe renal cell carcinoma (ChRCC) is important because their clinical behavior is different. As part of a search for the best available immunohistochemical markers to distinguish ChRCC from RO, we investigated the immunohistochemical profiles of these tumors. We selected 30 renal tumors consisting of ChRCC, typical variant (n = 14), ChRCC, eosinophilic variant (n = 6), and RO (n = 10). Their expression of cytokeratin (CK) 7, KAI1, epithelial-specific antigen (ESA), epithelial-related antigen (ERA), Claudin- 7, and Claudin-8 was studied using an autostainer. Immunoreactivity was assessed based on a combined score of the extent and intensity of staining. Compared to RO, a significantly higher percentage of the total ChRCCs stained positive for CK7 (85% vs. 10%, respectively), KAI1 (90% vs. 10%), ESA (95% vs. 10%), ERA (95% vs. 10%), and Claudin-7 (95% vs. 20%) (P &lt; 0.001). Additionally, there was a significant difference between the percentage of ChRCC eosinophilic variant (ChRCC-E) and RO that stained positive for KAI1 (100% vs. 10%, respectively), ESA (83% vs. 10%), and ERA (83% vs. 10%) (P &lt; 0.001). We recommend immunohistochemical analysis of KAI1, ESA, and ERA to distinguish ChRCC-E from RO.

    DOI: 10.1007/s00795-011-0546-3

  • Neo-adjuvant Chemoradiation Therapy Using S-1 Followed by Surgical Resection in Patients with Pancreatic Cancer

    Sohei Satoi, Hideyoshi Toyokawa, Hiroaki Yanagimoto, Tomohisa Yamamoto, Minoru Kamata, Chisato Ohe, Noriko Sakaida, Yoshiko Uemura, Hiroaki Kitade, Noboru Tanigawa, Kentaro Inoue, Yoichi Matsui, A-Hon Kwon

    JOURNAL OF GASTROINTESTINAL SURGERY   16 ( 4 )   784 - 792   2012年04月( ISSN:1091-255X

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    The aim of this study was to compare short-term surgical results in pancreatic cancer patients who underwent surgical resection after neo-adjuvant chemoradiation therapy (NACRT) using S-1.
    The study population comprised 77 patients with pancreatic cancer between 2006 and 2010. Out of 34 patients who underwent staging laparoscopy between 2008 and 2010, 31 patients without occult distant organ metastasis underwent chemoradiation and of whom 30 underwent pancreatectomy (NACRT group). Of the other 43 patients, 36 underwent surgical resection in 2006-2008, followed by adjuvant therapy (adjuvant group). The primary endpoint was frequency of pathological curative resection (R0).
    The new regimen of NACRT was feasible and safe. Twenty-eight of 30 (93%) patients in the NACRT group had R0 resection, which was significantly higher than in the adjuvant group (21 of 36 patients, 58%, p = 0.005). The number and extent of metastatic lymph nodes in the NACRT group (1 (0-25), N0/1; 18 of 38) was significantly lower than in the adjuvant group (2 (0-19), N0/1; 23 of 30), p = 0.0363). The frequency of intractable ascites in the NACRT group (eight of 30) was significantly higher than in the adjuvant group (two of 36, p = 0.035).
    Neo-adjuvant chemoradiation therapy using S-1 followed by pancreatectomy can improve the rate of pathologically curative resection and reduces the number and extent of lymph node metastasis.

    DOI: 10.1007/s11605-011-1795-0

  • Autoimmune Pancreatitis with Histologically Proven Lymphoplasmacytic Sclerosing Pancreatitis with Granulocytic Epithelial Lesions 査読

    Tsukasa Ikeura, Makoto Takaoka, Kazushige Uchida, Masaaki Shimatani, Hideaki Miyoshi, Takeo Kusuda, Akiko Kurishima, Yuri Fukui, Kimi Sumimoto, Sohei Satoi, Chisato Ohe, Yoshiko Uemura, A-Hon Kwon, Kazuichi Okazaki

    INTERNAL MEDICINE   51 ( 7 )   733 - 737   2012年( ISSN:0918-2918

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Recent histological and clinical studies have suggested the existence of 2 distinct types of autoimmune pancreatitis (AIP): type 1 AIP related to IgG4, exhibiting lymphoplasmacytic sclerosing pancreatitis (LPSP), and type 2 AIP related to granulocyte epithelial lesions (GELs), exhibiting idiopathic duct-centric chronic pancreatitis (IDCP). We herein present a case of type 1 AIP with histologically proven LPSP with GELs. This patient had neither serum IgG4 elevation nor MPD narrowing. In this case, the clinically and histologically atypical findings for type 1 AIP are intriguing.

    DOI: 10.2169/internalmedicine.51.6859

  • Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study 査読

    Naoto Kuroda, Tomoyuki Shiotsu, Chiaki Kawada, Taro Shuin, Ondrej Hes, Michal Michal, Chisato Ohe, Shuji Mikami, Chin-Chen Pan

    ANNALS OF DIAGNOSTIC PATHOLOGY   15 ( 4 )   282 - 285   2011年08月( ISSN:1092-9134

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Clear cell papillary renal cell carcinoma (RCC) is a recently established disease entity. However, there are few reports on genetic study of this entity. We report such a case with focus on genetic study. A 57-year-old Japanese man was found to have 3 renal tumors. Histologically, two tumors showed findings of clear cell RCC; and the other tumor showed findings of clear cell papillary RCC that was characterized by papillary growth pattern of neoplastic cells in cystic space with purely clear cell cytology. Immunohistochemically, tumor cells of clear cell papillary RCC were diffusely positive for PAX2 and cytokeratin 7, but negative for CD 10, RCC Ma, and AMACR. In fluorescence in situ hybridization study for one clear cell papillary RCC, we detected polysomy for chromosome 7 and monosomy for chromosomes 17, 16, and 20. In addition, we detected mutation of VHL gene in clear cell RCC, but found no VHL gene mutation in clear cell papillary RCC. Finally, our results provide further evidence that clear cell papillary RCC may be both morphologically and genetically distinct entity from clear cell RCC and papillary RCC. (C) 2011 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.anndiagpath.2010.03.007

  • Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma 査読

    Naoto Kuroda, Naoki Kanomata, Tadanori Yamaguchi, Yoshiaki Imamura, Chisato Ohe, Noriko Sakaida, Ondrej Hes, Michal Michal, Taro Shuin, Gang-Hong Lee

    MEDICAL MOLECULAR MORPHOLOGY   44 ( 2 )   111 - 115   2011年06月( ISSN:1860-1480

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    S100A1 is a calcium-binding protein and a member of the S100 family. Recently, S100A1 immunohistochemistry may be an available marker in the differential diagnosis between renal oncocytoma and chromophobe renal cell carcinoma (RCC). However, there are no reports on S100A1 expression in oncocytic papillary RCC that has been recently identified. In this article, we immunohistochemically examined the expression of S100A1 protein in 18 renal tumors including 4 renal oncocytoma, 10 chromophobe RCCs, and 4 oncocytic papillary RCCs. All the cases of renal oncocytoma and oncocytic papillary RCC showed a positive reaction for S100A1 with cytoplasmic pattern. In chromophobe RCC, 3 of 4 tumors with typical variant and 4 of 6 tumors in eosinophilic variant were completely negative for S100A1. Finally, S100A1 immunohistochemistry may be useful in distinguishing renal oncocytoma from chromophobe RCC, but it may be of no use in the differential diagnosis between renal oncocytoma and oncocytic papillary RCC.

    DOI: 10.1007/s00795-009-0461-z

  • Clear cell renal cell carcinoma with focal renal angiomyoadenomatous tumor-like area 査読

    Naoto Kuroda, Tadanori Hosokawa, Michal Michal, Ondrej Hes, Radek Sima, Chisato Ohe, Gang-Hong Lee

    ANNALS OF DIAGNOSTIC PATHOLOGY   15 ( 3 )   202 - 206   2011年06月( ISSN:1092-9134

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Recently, renal angiomyoadenomatous tumor (RAT) has been identified. However, there are no descriptions about clear cell renal cell carcinoma (RCC) with focal RAT-like features. A 33-year-old Japanese man was found to have a tumor in the left kidney. Macroscopically, the tumor extended into the perinephric fat tissue, and the cut surface showed the yellowish color. The histologic examination of the tumor consisted of 2 components of clear cell RCC and RAT-like area. The RAT-like area showed the admixture of epithelial cells with basophilic or clear cytoplasm and stromal component containing leiomyomatous stroma, fine capillary network, and pericytic network. Immunohistochemically, epithelial neoplastic cells in RAT-like area were diffusely positive for CD10 and RCC Ma. G-band karyotype showed the structural abnormality of chromosome 3 and both components of clear cell RCC and RAT-like area revealed the identical VHL gene mutation. Finally, pathologists should pay attention to the presence of clear cell RCC focally resembling RAT. (C) 2011 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.anndiagpath.2010.03.003

  • A case of splenic low-grade mucinous cystadenocarcinoma resulting in pseudomyxoma peritonei 査読

    Chisato Ohe, Noriko Sakaida, Yasuaki Yanagimoto, Hideyoshi Toyokawa, Sohei Satoi, A-Hon Kwon, Chika Tadokoro, Kosho Takasu, Yoshiko Uemura

    MEDICAL MOLECULAR MORPHOLOGY   43 ( 4 )   235 - 240   2010年12月( ISSN:1860-1480

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)  

    Primary splenic mucinous cystadenocarcinoma (MCCa) is extremely rare, and only six cases appear to have been reported previously. We present herein a case of primary splenic MCCa resulting in pseudomyxoma peritonei (PMP). A 66-year-old Japanese woman presented to a hospital with a chief complaint of upper abdominal pain and a 7-year history of splenic cyst. Cyst rupture was noted on computed tomography, and splenectomy was performed. The abdominal cavity was filled with a large amount of gelatinous ascites, with the appearance of PMP. On the cut surface, multiple cysts containing mucinous material were found within and outside the spleen. Microscopically, splenic parenchyma was occupied by large mucinous pools focally lined with mucinous epithelial cells and mesothelial cell-like cells, which were considered benign. Outside the spleen, a low-grade MCCa component was found. No ectopic pancreatic or intestinal tissue was identified. Although most PMP cases are known to be caused by low-grade mucinous appendiceal tumor, the present case represents the first report of a splenic MCCa resulting in PMP.

    DOI: 10.1007/s00795-010-0507-2

  • A unique renal cell carcinoma with features of papillary renal cell carcinoma and thyroid-like carcinoma: a morphological, immunohistochemical and genetic study 査読

    Chisato Ohe, Naoto Kuroda, Chin-Chen Pan, Ximing J. Yang, Ondrej Hes, Michal Michal, Hirofumi Uehara, Shuji Hamada, Shigeru Kirime, Hideto Senzaki

    HISTOPATHOLOGY   57 ( 3 )   494 - 497   2010年09月( ISSN:0309-0167

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/j.1365-2559.2010.03631.x

  • Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: Report of two cases 査読

    Chisato Ohe, Noriko Sakaida, Chika Tadokoro, Hideto Fukui, Mikiya Asako, Koichi Tomoda, Yoshiko Uemura

    PATHOLOGY INTERNATIONAL   60 ( 2 )   107 - 111   2010年02月( ISSN:1320-5463

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (LGNPPA) is extremely rare; only four cases have been reported. Herein are presented the case reports of two Japanese male patients with thyroid-like LGNPPA. Macroscopically, these tumors were pedunculated polypoid masses on the roof of the nasopharynx. Microscopically, they were characterized by papillary and glandular epithelial proliferation. The papillae were complex and tightly packed with hyalinized fibrovascular cores and lined by columnar and pseudostratified cells with intervening spindle-shaped cells. Both cell types had round to oval vesicular nuclei with tiny nucleoli and mildly eosinophilic cytoplasm. Mitotic figures were not evident and necrosis was not observed. Psammoma bodies were seen focally in one of the patients. Transition from normal surface epithelium to tumor cells was identified in both cases. On immunohistochemistry the tumor cells were positive for cytokeratin (CK) 7, CK19, thyroid transcription factor-1 (TTF-1) and vimentin. They were negative for CK5/6, CK20, thyroglobulin, S-100 protein and CD15. In situ hybridization for EBV was negative. Nasopharyngeal tumors with similar morphological appearance should be examined for TTF-1 immunoreactivity, and patients should be clinically followed to determine the course of this unusual disease and the significance of TTF-1 expression.

    DOI: 10.1111/j.1440-1827.2009.02480.x

  • Renal carcinoid tumor: An immunohistochemical and molecular genetic study of four cases 査読

    Naoto Kuroda, Isabel Alvarado-Cabrero, Radek Sima, Ondrej Hes, Michal Michal, Hidefumi Kinoshita, Tadashi Matsuda, Chisato Ohe, Noriko Sakaida, Yoshiko Uemura, Gang-Hong Lee

    ONCOLOGY LETTERS   1 ( 1 )   87 - 90   2010年01月( ISSN:1792-1074

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Few genetic studies of renal carcinoid tumor have been conducted thus far We performed immunohistochemical and genetic examinations on four renal carcinoid tumors Histologically, the tumors consisted of neoplasm cells with round to oval nuclei Various growth patterns such as tightly packed cords and trabeculae, ribbon-like, trabecular, sheet-like or solid growth were observed Nuclear chromatin showed a coarse and granular pattern Immunohistochemically, tumors were positive for chromogranin A and synaptophysin In the fluorescence in situ hybridization study, three of four tumors revealed monosomy of chromosome 3 (D3Z1), but one tumor showed monosomy of chromosome 13 (D13S319/13q34) Using PCR amplification and fragment analysis of three microsatellite markers (D3S1300, D3S666 and D3S1768) of chromosome arm 3p, one tumor showed loss of heterozygosity at D3S1300 and D3S1768, one tumor was not informative and the analysis of two tumors failed due to low DNA quality In three cases, the VHL gene status was tested Two tumors showed wild-type but the analysis of one tumor failed to provide adequate results In conclusion, we suggest that the abnormality of chromosome 3 is involved in the pathogenesis of renal carcinoid tumor

    DOI: 10.3892/ol_00000015

  • Renal angiomyoadenomatous tumor: fluorescence in situ hybridization 査読

    Naoto Kuroda, Michal Michal, Ondrej Hes, Takahiro Taguchi, Akira Tominaga, Kohichi Mizobuchi, Chisato Ohe, Noriko Sakaida, Yoshiko Uemura, Taro Shuin, Gang-Hong Lee

    PATHOLOGY INTERNATIONAL   59 ( 9 )   689 - 691   2009年09月( ISSN:1320-5463

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/j.1440-1827.2009.02429.x

  • Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity 査読

    M. Michal, O. Hes, J. Nemcova, R. Sima, N. Kuroda, S. Bulimbasic, M. Franco, N. Sakaida, D. Danis, D. V. Kazakov, C. Ohe, M. Hora

    VIRCHOWS ARCHIV   454 ( 1 )   89 - 99   2009年01月( ISSN:0945-6317

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    We present a series of a distinct tumorous entity named renal angiomyoadenomatous tumor (RAT). Five cases were retrieved from the consultation files of the authors. Histologic and immunohistochemical features were evaluated. Sequencing analysis of coding region of the VHL gene was carried out in all cases. The tumors were composed of admixture of an epithelial clear cell component and prominent leiomyomatous stroma. Epithelial cells formed adenomatous tubular formations endowed with blister-like apical snouts. All tubular/glandular structures were lined by a fine capillary network. The epithelial component was positive for epithelial membrane antigen, CK7, CK20, AE1-AE3, CAM5.2, and vimentin in all cases. In all analyzed samples, no mutation of the VHL gene was found. RAT is a distinct morphologic entity, being different morphologically, immunohistochemically, and genetically from all renal tumors including conventional clear cell carcinoma and mixed epithelial and stromal tumor of kidney.

    DOI: 10.1007/s00428-008-0697-3

▼全件表示

書籍等出版物

  • 腎癌

    大江 知里, 長嶋 洋治, 腫瘍病理鑑別診断アトラス刊行委員会, 日本病理学会

    文光堂  2023年  ( ISBN:9784830622663

     詳細を見る

  • 第Ⅱ章GCNIS由来胚細胞腫瘍 奇形腫, 思春期後型「精巣腫瘍アトラス」

    大江知里( 担当: 分担執筆)

    文光堂  2021年06月 

     詳細を見る

    担当ページ:67-73   著書種別:学術書  

  • 第Ⅲ章 診断に有用な免疫組織化学および遺伝子検索 性索間質性腫瘍「精巣腫瘍アトラス」

    大江知里( 担当: 分担執筆)

    文光堂  2021年06月 

     詳細を見る

    担当ページ:217-224   著書種別:学術書  

  • 第2部病理学的事項「腎癌取扱い規約 第5版」

    長嶋洋治, 三上修治, 大江知里, 林博之( 担当: 共著)

    メディカルレビュー社  2020年12月 

     詳細を見る

    担当ページ:55-106   著書種別:学術書  

  • 2章 診断のための基本知識 泌尿器腫瘍の免疫染色「腎・尿路/男性生殖器腫瘍 (癌診療指針のための病理診断プラクティス)」

    古里文吾, 大江知里( 担当: 共著)

    中山書店  2016年08月 

     詳細を見る

    担当ページ:58-69   著書種別:学術書  

  • 3章 腎腫瘍の概要と鑑別診断 腎腫瘍針生検診断のコツ「腎・尿路/男性生殖器腫瘍 (癌診療指針のための病理診断プラクティス)」

    大江知里( 担当: 単著)

    中山書店  2016年08月 

     詳細を見る

    担当ページ:154-161   著書種別:学術書  

  • Renal cell carcinoma, subsequent second tumor,Diagnostic Pathology, Genitourinary, second edition

    Satish K. Tickoo, Chisato Ohe, Victor E. Reuter( 担当: 共著)

    Amirsys  2016年 

     詳細を見る

    担当ページ:138-141   著書種別:学術書  

  • 腎腫瘍の免疫組織化学「腫瘍病理鑑別診断アトラス 腎癌」

    大江知里( 担当: 単著)

    文光堂  2013年11月  ( ISBN:9784830622397

     詳細を見る

    担当ページ:17-26   著書種別:学術書  

▼全件表示

MISC(その他記事)

  • The academic impact and value of an international online surgery lecture series(タイトル和訳中)

    Hashimoto Daisuke, Gulla Aiste, Satoi Sohei, Yamamoto Tomohisa, Yamaki So, Matsui Yuki, Ohe Chisato, Yamasaki Makoto, Hamada Madoka, Ikeura Tsukasa, Shimatani Masaaki, Breugelmans Raoul, Utkus Algirdas, Poskus Tomas, Samuilis Arturas, Miglinas Marius, Laurinavicius Arvydas, Tomoda Koichi, Hendrixson Vaiva, Sekimoto Mitsugu, Strupas Kestutis

    Surgery Today   53 ( 9 )   1100 - 1104   2023年09月( ISSN:0941-1291

  • 鑑別の森(第23回) 腎臓の淡明細胞型腎細胞癌と転座型腎細胞癌 Answer(1)

    大江 知里

    病理と臨床   41 ( 8 )   0866 - 0869   2023年08月( ISSN:0287-3745

  • Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma(タイトル和訳中)

    Yoshida Takashi, Ohe Chisato, Nakamoto Takahiro, Kinoshita Hidefumi

    International Journal of Urology   30 ( 8 )   634 - 647   2023年08月( ISSN:0919-8172

  • 尿路上皮癌におけるWHO分類第5版の改訂ポイント

    大江 知里, 塩原 正規, 都築 豊徳

    診断病理   40 ( 3 )   226 - 234   2023年07月( ISSN:1345-6431

     詳細を見る

    現在,様々な臓器においてWHO分類第5版シリーズが発刊されているが,その改訂コンセプトとしては,最新の分子生物学的成果を含めた治療効果予測に繋がる分類の採用,全世界で使用できるよう形態像を重視した分類に基づく必須の診断基準,画像診断の重要性の強調などが挙げられる。本総説では,尿路上皮癌に焦点を当ててWHO分類第5版の改訂点を概説する。主な改訂点は1)非浸潤性尿路上皮腫瘍の用語の改訂,2)細胞診におけるThe Paris Systemの使用の推奨,3)浸潤性尿路上皮癌における分子生物学的分類の位置づけ,4)pTステージの評価におけるVesical Imaging Reporting and Data System(VI-RADS)の併用の推奨であり,各項目について解説する。(著者抄録)

  • 【泌尿器病理 鳥瞰図-近未来の泌尿器腫瘍へズームイン】腎癌 淡明細胞型腎細胞癌の病理学的総説と予後予測因子

    大江 知里, 中本 喬大, 吉田 崇

    臨床泌尿器科   77 ( 7 )   484 - 490   2023年06月( ISSN:0385-2393

     詳細を見る

    <文献概要>ポイント ・淡明細胞型腎細胞癌はVHL遺伝子異常を反映した組織形態を示し,繊細で豊富な血管網を背景に淡明や好酸性の腫瘍細胞が増殖する.・CA9はVHL/HIF経路に関連する蛋白で,細胞膜にびまん性に陽性を示すと淡明細胞型腎細胞癌としての診断的価値が高い.・血管網が消失する組織構築では免疫系の遺伝子発現が高く,予後不良と関連する.

  • 今月の話題 淡明細胞型腎細胞癌の好酸性細胞領域からどのような情報が得られるか?

    大江 知里

    病理と臨床   41 ( 5 )   0533 - 0535   2023年05月( ISSN:0287-3745

  • 【病理診断クイックリファレンス 2023】(第10章)腎(腫瘍)・尿路 乳頭状腎細胞癌

    大江 知里

    病理と臨床   41 ( 臨増 )   139 - 139   2023年04月( ISSN:0287-3745

  • 【尿路系腫瘍の現在-WHO2022の根幹に触れる-】膀胱癌の分子サブタイプと免疫表現型

    吉田 崇, 池田 純一, 大江 知里

    病理と臨床   41 ( 4 )   0405 - 0412   2023年04月( ISSN:0287-3745

  • 【病理診断クイックリファレンス 2023】(第10章)腎(腫瘍)・尿路 集合管癌

    大江 知里

    病理と臨床   41 ( 臨増 )   141 - 141   2023年04月( ISSN:0287-3745

  • Oncocytic and chromophobe renal tumorの鑑別診断

    大橋 瑠子, 大江 知里, 橋立 英樹, 大月 寛郎, 山田 鉄也, 宮崎 龍彦, 都築 豊徳, 長嶋 洋治

    診断病理   40 ( 1 )   18 - 31   2023年01月( ISSN:1345-6431

     詳細を見る

    オンコサイトーマと嫌色素性腎細胞癌を代表組織型とするoncocytic and chromophobe renal tumorの鑑別診断は広範囲に及び,日常診断でしばしば難渋する。本総説ではWHO泌尿生殖器腫瘍分類第5版(以下,WHO2022)におけるオンコサイトーマと嫌色素性腎細胞癌の診断基準の改定点と,両者の鑑別診断について解説する。また,WHO2022では新たにother oncocytic tumors of the kidneyという項目が加わった。そのあらましと,本項目に含まれる腫瘍群の特徴について紹介する。(著者抄録)

  • 新型コロナパンデミック下における医学生の国際的学術交流 病理医としての試み

    大江 知里

    病理と臨床   40 ( 5 )   0499 - 0502   2022年05月( ISSN:0287-3745

  • Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report 査読

    Suzuki K, Harada H, Takeda M, Ohe C, Uemura Y, Kawahara A, Sawada S, Kanda A, Sengupta B, Iwai H.

    BMC medical genomics   15 ( 1 )   6   2022年01月( ISSN:1755-8794 ( eISSN:1755-8794

  • Familial Hyperaldosteronism Type 3 with a Rapidly Growing Adrenal Tumor: An In Situ Aldosterone Imaging Study 査読

    Takizawa N, Tanaka S, Nishimoto K, Sugiura Y, Suematsu M, Ohe C, Ohsugi H, Mizuno Y, Mukai K, Seki T, Oki K, Gomez-Sanchez C. E Matsuda T

    Current issues in molecular biology   44 ( 1 )   128 - 138   2022年01月( ISSN:1467-3037

     詳細を見る

  • 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 切除不能肝細胞癌に対するアテゾリズマブ+ベバシズマブ療法の腫瘍縮小効果

    小坂 久, 松井 康輔, 大江 知里, 松島 英之, 山本 栄和, 関本 貢嗣, 海堀 昌樹

    肝胆膵   83 ( 2 )   251 - 257   2021年08月( ISSN:0389-4991

  • SWI/SNF-deficient neoplasms of the genitourinary tract. 査読

    Sirohi D MD, Ohe C, Smith SC, Amin MB.

    Semin Diagn Pathol.   38 ( 3 )   212 - 221   2021年05月

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.1053/j.semdp.2021.03.007

  • 【治療方針を変える病理所見 診療ガイドラインと治療戦略】(第1部)臓器別 腎

    大江 知里, 吉田 崇, 大杉 治之, 黒田 直人, 長嶋 洋治

    病理と臨床   39 ( 臨増 )   156 - 162   2021年04月( ISSN:0287-3745

  • 「腎癌取扱い規約 第5版」改訂ポイント 招待

    長嶋 洋治, 林 博之, 大江 知里, 三上 修治

    病理と臨床   39 ( 2 )   171 - 174   2021年02月

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)   国際・国内誌:国内誌  

  • 切り出しのキモ 私はここをこう切っている(第11回) 腎臓

    長嶋 洋治, 大江 知里, 林 博之, 三上 修治

    病理と臨床   39 ( 2 )   179 - 183   2021年02月( ISSN:0287-3745

  • 速報解説!ここが変わった 「腎癌取扱い規約 第5版」改訂ポイント

    長嶋 洋治, 林 博之, 大江 知里, 三上 修治

    病理と臨床   39 ( 2 )   171 - 174   2021年02月( ISSN:0287-3745

  • Review of TFEB-amplified renal cell carcinoma with focus on clinical and pathobiological aspects 査読

    Kuroda N, Sugawara E, Ohe C, Kojima F, Ohashi R, Mikami S, Nagashima Y, Peckova K, Michal M, Hes O.

    Polish journal of pathology   72 ( 3 )   197 - 199   2021年( ISSN:1233-9687

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)   国際・国内誌:国際誌  

    DOI: 10.5114/pjp.2021.111769

    PubMed

  • 【免疫組織化学 実践的な診断・治療方針決定のために】(第3部)腫瘍の鑑別に用いられる抗体(各臓器別) 腎

    大江 知里, 黒田 直人, 長嶋 洋治

    病理と臨床   38 ( 臨増 )   149 - 154   2020年04月( ISSN:0287-3745

  • 類上皮型腎血管筋脂肪腫の臨床学的および病理学的側面に焦点を当てた文献レビュー(Review of renal epithelioid angiomyolipoma with focus on clinical and pathobiological aspects)

    Kuroda Naoto, Yorita Kenji, Ohe Chisato, Kojima Fumiyoshi, Kato Ikuma, Mikami Shuji, Furuya Motsuko, Nagashima Yoji, Pan Chin-Chen, Lopez Jose Ignacio, Hes Ondrej, Michal Michal, Amin Mahul B.

    高知赤十字病院医学雑誌   24 ( 1 )   29 - 34   2020年03月( ISSN:0919-7427

  • 皮膚生検で診断が可能となった遺伝性平滑筋腫症と腎細胞癌症候群(Hereditary leiomyomatosis and renal cell cancer syndrome in which skin biopsy enabled diagnosis)

    Matsuda Tomoko, Kambe Naotomo, Nhung Thi My Ly, Ueda-Hayakawa Ikuko, Yamazaki Fumikazu, Ohe Chisato, Yoshida Kenji, Kinoshita Hidefumi, Furuya Mitsuko, Okamoto Hiroyuki

    The Journal of Dermatology   46 ( 8 )   e285 - e287   2019年08月( ISSN:0385-2407

  • High grade infiltrative adenocarcinomas of renal cell origin: New insights into classification, morphology, and molecular pathogenesis 査読

    Jaime A Singh, Chisato Ohe, Steven Christopher Smith

    Pathology International   68 ( 5 )   265 - 277   2018年05月( ISSN:1440-1827

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Collecting duct carcinoma was described over 30 years ago as a renal tumor, based in the medullary collecting system, with tubulopapillary morphology, prominent infiltrative growth, and stromal desmoplasia. While diagnostic workup has always emphasized exclusion of upper tract urothelial carcinoma and metastatic adenocarcinoma to the kidney, the molecular era of renal cell carcinoma classification has enabled recognition of and provided tools for diagnosis of new entities in this morphologic differential. In this review, we consider these developments, with emphasis on renal medullary carcinoma, closely related renal cell carcinoma, unclassified with medullary phenotype, and fumarate hydratase-deficient renal cell carcinoma. Integration of ancillary studies with suggestive patterns of morphology is emphasized for practical implementation in contemporary diagnosis, and several emerging tumor types in the morphologic differential are presented.

    DOI: 10.1111/pin.12667

  • 【病理診断の新潮流】 泌尿器系領域におけるAJCC/UICC第8版の改訂事項

    大江 知里, 都築 豊徳

    腎臓内科・泌尿器科   7 ( 3 )   280 - 285   2018年03月( ISSN:2188-9147

     詳細を見る

    担当区分:筆頭著者   掲載種別:記事・総説・解説・論説等(学術雑誌)   国際・国内誌:国内誌  

  • 【免疫チェックポイント療法と病理】 泌尿器系腫瘍の病理診断と免疫チェックポイント療法

    大江 知里, 都築 豊徳

    病理と臨床   36 ( 1 )   47 - 54   2018年01月( ISSN:0287-3745

     詳細を見る

    担当区分:筆頭著者   掲載種別:記事・総説・解説・論説等(学術雑誌)   国際・国内誌:国内誌  

  • 【腎臓の腫瘍】 知っておくべき腎細胞癌以外の腎腫瘍

    黒田直人, 大江知里, 小島史好, 林博之

    病理と臨床   35 ( 10 )   941 - 945   2017年10月

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)   国際・国内誌:国内誌  

  • 【尿路上皮腫瘍:変わりつつある概念】 内反性増殖を示す尿路上皮性腫瘍

    大江 知里

    病理と臨床   35 ( 9 )   817 - 823   2017年09月( ISSN:0287-3745

     詳細を見る

    担当区分:筆頭著者   掲載種別:記事・総説・解説・論説等(学術雑誌)   国際・国内誌:国内誌  

  • S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers 査読

    Moushumi Suryavanshi, Julian Sanz-Ortega, Deepika Sirohi, Mukul K. Divatia, Chisato Ohe, Claudia Zampini, Daniel Luthringer, Steven C. Smith, Mahul B. Amin

    ADVANCES IN ANATOMIC PATHOLOGY   24 ( 3 )   151 - 160   2017年05月( ISSN:1072-4109 ( eISSN:1533-4031

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    S100P, or placental S100, is a member of a large family of S100 proteins and considered to be a promising immunohistochemical marker to support urothelial differentiation. This review synthesizes published data regarding the expression of S100P in urothelial carcinoma across histological grade and variant patterns, and in other malignancies, in an effort to summarize the state of understanding of this marker and evaluate its potential. We provide also a broad comparison of S100P with other contemporary and traditional urothelial markers and outline the potential utility of S100P in various diagnostically challenging scenarios. Taken in context, we recommend that to provide immunohistochemical support for consideration of urothelial differentiation, S100P may be included in a panel of markers (due to its high sensitivity), with better established (GATA3) and more specific (uroplakin 2) markers, for comparison with corresponding markers of other primary sites under consideration, depending on the clinical context. We emphasize that the overall most appropriate panel for any given case depends on the differential diagnosis engendered by the morphology encountered, and the constellation of clinical findings. As always with immunohistochemical panels, expected positive and negative markers for each diagnostic consideration should be included. Finally, since as of date there are no optimally sensitive or specific markers of urothelial differentiation, all final diagnoses relying on immunohistochemical support should be made in the appropriate clinical and histological context.

    DOI: 10.1097/PAP.0000000000000150

  • Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors 査読

    Naoto Kuroda, Chisato Ohe, Ikuma Kato, Mitsuko Furuya, Masaya Baba, Yoji Nagashima, Yukio Nakatani, Ichiro Murakami, Ming Zhou, Michal Michal, Ondrej He, Mahul B. Amin

    Polish Journal of Pathology   68 ( 4 )   284 - 290   2017年( ISSN:1233-9687

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    The entity of hereditary leiomyomatosis renal cell carcinoma (HLRCC)-associated RCC has been proposed and integrated into the recent International Society of Urologic Pathology (ISUP) of renal tumors. This tumor is characterized by presence of cutaneous and/or uterine leiomyomas and RCC and autosomal dominant hereditary form. Grossly, HLRCC arising in the kidney show the solid tumor with frequent partial cystic area. Microscopically, the tumor typically shows papillary RCC, type 2, with eosinophilic large nucleoli reminiscent of cytomegaloviral inclusion and perinuclear clearing/haloes. Immunohistochemically, tumor cells show the overexpression for 2SC and reduced expression of FH. Germline mutation of fumarate hydratase (FH) gene, the HLRCC responsible gene mapped to chromosome 1q43, has been identified in patients with HLRCC. As the renal cancer in patients with HLRCC generally behave aggressively even in a small size, complete surgical resection and retroperitoneal lymph node resection should be performed promptly when the tumor is discovered. The surveillance of renal tumor in FH gene germline mutation-positive patients should be started from the early age using ultrasound sonography or magnetic resonance imaging.

    DOI: 10.5114/pjp.2017.73920

    PubMed

  • REVIEW OF SUCCINATE DEHYDROGENASE-DEFICIENT RENAL CELL CARCINOMA WITH FOCUS ON CLINICAL AND PATHOBIOLOGICAL ASPECTS 査読

    Naoto Kuroda, Kenji Yorita, Makoto Nagasaki, Yuji Harada, Chisato Ohe, Jera Jeruc, Maria Rosaria Raspollini, Michal Michal, Ondrej Hes, Mahul B. Amin

    POLISH JOURNAL OF PATHOLOGY   67 ( 1 )   3 - 7   2016年( ISSN:1233-9687

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC) was first identified in 2004 and has been integrated into the 2016 WHO classification of RCC. Succinate dehydrogenase (SDH) is an enzyme complex composed of four protein subunits (SDHA, SDHB, SDHC and SDHD). The tumor which presents this enzyme mutation accounts for 0.05 to 0.2% of all renal carcinomas. Multiple tumors may occur in approximately 30% of affected patients. SDHB-deficient RCC is the most frequent, and the tumor histologically consists of cuboidal cells with eosinophilic cytoplasm, vacuolization, flocculent intracytoplasmic inclusion and indistinct cell borders. Ultrastructurally, the tumor contains abundant mitochondria. Immunohistochemically, tumor cells are positive for SDHA, but negative for SDHB in SDHB-, SDHC- and SDHD-deficient RCCs. However, SDHA-deficient RCC shows negativity for both SDHA and SDHB. In molecular genetic analyses, a germline mutation in the SDHB, SDHC or SDHD gene (in keeping with most patients having germline mutations in an SDH gene) has been identified in patients with or without a family history of renal tumors, paraganglioma/pheochromocytoma or gastrointestinal stromal tumor. While most tumors are low grade, some tumors may behave in an aggressive fashion, particularly if they are high nuclear grade, and have coagulative necrosis or sarcomatoid differentiation.

    DOI: 10.5114/PJP.2016.59227

  • REVIEW OF RENAL CELL CARCINOMA WITH RHABDOID FEATURES WITH FOCUS ON CLINICAL AND PATHOBIOLOGICAL ASPECTS 査読

    Naoto Kuroda, Takashi Karashima, Keiji Inoue, Atsuko Kasajima, Chisato Ohe, Fumi Kawakami, Shuji Mikami, Keiko Matsuura, Masatsugu Moriyama, Yoji Nagashima, Fredrik Fetersson, Jose I. Lopez, Ronald J. Cohen, Michal Michal, Ondrej Hes

    POLISH JOURNAL OF PATHOLOGY   66 ( 1 )   3 - 8   2015年03月( ISSN:1233-9687

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Rhabdoid morphology in renal cell carcinoma (RCC) may, like sarcomatoid change, be perceived as a type of dedifferentiation, and is a poor prognostic factor. Histologically, rhabdoid neoplastic cells are round to polygonal cells with globular eosinophilic cytoplasmic inclusions and eccentric vesicular nuclei and enlarged nucleoli. All types of RCC, including clear cell, papillary, chromophobe, collecting duct carcinoma, renal medullary carcinoma, acquired cystic disease-associated RCC, ALK-positive renal cancer and unclassified RCC, may display a variably prominent rhabdoid phenotype. Immunohistochemically, the cytoplasm of rhabdoid cells shows positivity for vimentin and/or cytokeratin. Ultrastructurally, cytoplasmic whorls/aggregates of intermediate filaments correspond to light microscopically observed inclusions. Genetically, a previous report suggests that combined loss of BAP1 and PBRM1 may be associated with rhabdoid morphology. As with sarcomatoid change, pathologists should describe, estimate and state the proportion of tumor cells with a rhabdoid phenotype in the routine pathology report of RCC.

    DOI: 10.5114/PJP.2015.51147

  • 【免疫組織化学 診断と治療選択の指針】 腫瘍の鑑別に用いられる抗体 腎

    大江知里, 黒田直人, 長嶋洋治

    病理と臨床   32 ( 臨時増刊 )   160-165   2014年04月( ISSN:0287-3745

     詳細を見る

    担当区分:筆頭著者   掲載種別:記事・総説・解説・論説等(学術雑誌)  

  • Clear cell papillary renal cell carcinoma: a review 査読

    Naoto Kuroda, Chisato Ohe, Fumi Kawakami, Shuji Mikami, Mitsuko Furuya, Keiko Matsuura, Masatsugu Moriyama, Yoji Nagashima, Ming Zhou, Fredrik Petersson, Jose I. Lopez, Ondrej Hes, Michal Michal, Mahul B. Amin

    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY   7 ( 11 )   7312 - 7318   2014年( ISSN:1936-2625

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    The disease concept of clear cell (tubulo) papillary renal cell carcinoma (CCP-RCC) as a distinct subtype of renal cell carcinoma has been recently established. First described in the setting of end stage renal disease, this tumor type is more frequently recognized and encountered in a sporadic setting. In this article, we provide an overview of the recent understanding of this tumor. Macroscopically, tumors are well circumscribed with well-developed tumor capsule. Histologically, the tumor cells are cuboidal to low columnar cell with clear cytoplasm and papillary and tubulo-papillary configuration. Immunohistochemically, tumor cells generally show diffuse expression for cytokeratin 7, CA9 (cup-shaped pattern), HIF-1, GLUT-1 and high molecular weight cytokeratin, but negative for AMACR, RCC Ma and TFE3. CD10 is negative or focally positive in most tumors. Genetically, this tumor has no characteristics of clear cell RCC or papillary RCC. Prognostically, patients with CCP-RCC behave in an indolent fashion in all previously reported cases. In conclusion, although this tumor has been integrated into recent International Society of Urologic Pathology Classification of renal neoplasia, both aspects of disease concept and clinical behavior are yet to be fully elucidated. Further publications of large cohorts of patients will truly help understand the biologic potential and the molecular underpinnings of this tumor type.

  • Solitary fibrous tumor of the kidney with focus on clinical and pathobiological aspects 査読

    Naoto Kuroda, Chisato Ohe, Noriko Sakaida, Yoshiko Uemura, Keiji Inoue, Yoji Nagashima, Ondrej Hes, Michal Michal

    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY   7 ( 6 )   2737 - 2742   2014年( ISSN:1936-2625

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Renal solitary fibrous tumor (SFT) is a rare, and a large scale study on this topic is lacking to date. In this article, we summarize the previously reported cases. The symptoms and signs resemble those of renal cell carcinoma, including hematuria, flank/abdominal/lumbar pain and palpable abdominal mass. Grossly, the tumor demonstrates a well-circumscribed solid mass. Microscopically, the tumor consists of fusiform or ovoid spindle cells and a various amounts of collagen bundles with patternless, storiform, or fascicular arrangements with an occasional hemangiopericytomatous pattern. Immunohistochemically, CD34, CD99 and bcl-2 are often detected. Ultrastructurally, tumor cells contain irregular nuclei, prominent Golgi apparatus, branching rough endoplasmic reticulum, variable numbers of mitochondria. Surgical resection is considered to be the gold standard therapy. Most of renal SFT are benign, but cases of approximately 10 to 15% behave in an aggressive fashion. All patients need to be on long-term follow-up because clinical behavior is rather unpredictable. As the molecular genetic study of renal SFTs is lacking, a large scale study will be desirable in the future.

  • REVIEW OF TUBULOCYSTIC CARCINOMA OF THE KIDNEY WITH FOCUS ON CLINICAL AND PATHOBIOLOGICAL ASPECTS 査読

    Naoto Kuroda, Hirofumi Matsumoto, Chisato Ohe, Shuji Mikami, Yoji Nagashima, Keiji Inoue, Delia Perez-Montiel, Fredrik Petersson, Michal Michal, Ondrej Hes, Ximing J. Yang

    POLISH JOURNAL OF PATHOLOGY   64 ( 4 )   233 - 237   2013年12月( ISSN:1233-9687

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Tubulocystic carcinoma of the kidney (TCK) is a recently established entity in renal neoplastic pathology. This review aims to give an overview of the clinical and pathobiological aspects of TCK. Grossly, the TCKs are well-demarcated multicystic lesions giving a "wrapped bubble" or "spongy" appearance. Microscopically, the tumors are composed of multiple, variably sized cysts separated by thin fibrous septa lacking ovarian stroma or desmoplastic reaction. The cysts are lined by tumor cells with eosinophilic cytoplasm and nuclear atypia of variable, but not infrequently of high grade corresponding to Fuhrman grade 3. A frequent association with papillary tumors has been reported. Recent molecular genetic studies of TCK have revealed distinct features separating this subset of renal cell carcinomas (RCCs) from other types of renal tumors including collecting duct carcinoma of Bellini and renal medullary carcinoma as well as pointing towards a close kinship with papillary RCC. Tubulocystic carcinoma of the kidney generally pursues an indolent clinical course. However, several cases with aggressive clinical behavior have been reported. We strongly feel that there is enough clinicopathological evidence to corroborate TCK as a separate entity and that it should be incorporated into the next WHO classification of renal tumors as a separate neoplastic category.

    DOI: 10.5114/PJP.2013.39329

  • Recent advances of immunohistochemistry for diagnosis of renal tumors 査読

    Naoto Kuroda, Azusa Tanaka, Chisato Ohe, Yoji Nagashima

    Pathology International   63 ( 8 )   381 - 390   2013年08月( ISSN:1320-5463

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    The recent classification of renal tumors has been proposed according to genetic characteristics as well as morphological difference. In this review, we summarize the immunohistochemical characteristics of each entity of renal tumors. Regarding translocation renal cell carcinoma (RCC), TFE3, TFEB and ALK protein expression is crucial in establishing the diagnosis of Xp11.2 RCC, renal carcinoma with t(6
    11)(p21
    q12), and renal carcinoma with ALK rearrangement, respectively. In dialysis-related RCC, neoplastic cells of acquired cystic disease-associated RCC are positive for alpha-methylacyl-CoA racemase (AMACR), but negative for cytokeratin (CK) 7, whereas clear cell papillary RCC shows the inverse pattern. The diffuse positivity for carbonic anhydrase 9 (CA9) is diagnostic for clear cell RCC. Co-expression of CK7 and CA9 is characteristic of multilocular cystic RCC. CK7 and AMACR are excellent markers for papillary RCC and mucinous tubular and spindle cell carcinoma. CD82 and epithelial-related antigen (MOC31) may be helpful in the distinction between chromophobe RCC and renal oncocytoma. WT1 and CD57 highlights the diagnosis of metanephric adenoma. The combined panel of PAX2 and PAX8 may be useful in the diagnosis of metastatic RCC. © 2013 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

    DOI: 10.1111/pin.12080

    PubMed

  • Review of renal carcinoid tumor with focus on clinical and pathobiological aspects 査読

    Naoto Kuroda, Azusa Tanaka, Chisato Ohe, Shuji Mikami, Yoji Nagashima, Keiji Inoue, Taro Shuin, Takahiro Taguchi, Akira Tominaga, Isabel Alvarado-Cabrero, Fredrik Petersson, Matteo Brunelli, Guido Martignoni, Michal Michal, Ondrej Hes

    Histology and Histopathology   28 ( 1 )   15 - 21   2013年01月( ISSN:0213-3911

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Renal carcinoid tumor is a rare neoplasm. In this article, we review this neoplasm with a focus on clinical and pathobiological aspects. The majority of patients present in the fourth to seventh decades, but there is no gender predilection. Clinically, patients with renal carcinoid tumor frequently present with abdominal, back or flank pain. This tumor is occasionally associated with horseshoe kidney and/or mature cystic teratoma located in the kidney. Macroscopically, these tumors are well demarcated with a lobulated appearance and yellow or tan-brown color cut surface. Microscopically, these tumors are composed of monomorphic round to polygonal cells with granular amphophilic to eosinophilic cytoplasm. Tumor cells are arranged in trabecular, ribbon-like, gyriform, insular, glandular and solid patterns. The nuclei are round to oval and with evenly distributed nuclear chromatin, frequently with a "salt and pepper"-pattern. Immunohistochemically, tumor cells demonstrate immunolabeling for chromogranin A and synaptophysin. Ultrastructurally, the neoplastic cells contain abundant dense core neurosecretory granules. In previous genetic studies, abnormalities of chromosomes 3 or 13 have been reported. The clinical behavior of renal carcinoid tumors is variable, but is more indolent than most renal cell carcinomas. Further investigations are warranted in order to elucidate the critical genetic abnormalities responsible for the pathogenesis of this rare entity in renal neoplastic pathology.

    PubMed

  • Review of renal oncocytosis (multiple oncocytic lesions) with focus on clinical and pathobiological aspects 査読

    Naoto Kuroda, Azusa Tanaka, Chisato Ohe, Shuji Mikami, Yoji Nagashima, Toyokazu Sasaki, Keiji Inoue, Ondrej Hes, Michal Michal, Matteo Brunelli, Guido Martignoni

    HISTOLOGY AND HISTOPATHOLOGY   27 ( 11 )   1407 - 1412   2012年11月( ISSN:0213-3911

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Renal oncocytosis is a recently established disease entity characterized by numerous oncocytic tumors and diffuse involvement of oncocytic changes in renal parenchymal epithelia. In this article, we review this disease with a focus on its clinical and pathobiological aspects. Clinically, renal oncocytosis may occur in a sporadic form without any underlying disease or may be associated with chronic renal failure/long-term hemodialysis. However, Birt-Hogg-Dube syndrome, characterized by skin tumors such as fibrofolliculoma or trichodiscoma, pulmonary lesions including bullae and spontaneous pneumothorax, and renal tumors should be evaluated in the differential diagnosis. The disease can develop either unilaterally or bilaterally. The involved renal parenchyma contains several to multiple brownish-colored nodules of varying size and is entirely replaced by lesions at the overt stage. Histologically, oncocytic tumors in both the dominant mass and smaller lesions encompass so-called hybrid tumor, chromophobe renal cell carcinoma (RCC), and renal oncocytoma (RO). Regarding renal parenchymal abnormalities, infiltrative growth of oncocytic cells, cortical cysts with oncocytic features, or extensive oncocytic change in non-neoplastic tubules can also be observed. Histochemical, immunohistochemical, and molecular genetic features of chromophobe RCC and RO arising in the setting of renal oncocytosis are generally identical to those in the sporadic type. However, hybrid tumors seem to be histologically distinct from chromophobe RCC and RO. In FISH analyses of some hybrid tumors, a gain of chromosomes 1, 2, 6, 10, and 17 was identified. In one tumor, no germ line mutation of folliculin gene was identified. Published data show that tumors follow a benign course. Further studies will be necessary to clarify the pathogenesis of renal oncocytosis.

  • Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects 査読

    Naoto Kuroda, Chisato Ohe, Shuji Mikami, Keiji Inoue, Yoji Nagashima, Ronald J. Cohen, Chin-Chen Pan, Michal Michal, Ondrej Hes

    HISTOLOGY AND HISTOPATHOLOGY   27 ( 8 )   969 - 974   2012年08月( ISSN:0213-3911

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Multilocular cystic renal cell carcinoma (MCRCC) accounts for approximately 1 to 2% of all renal tumors. This tumor is currently classified as a subtype of clear cell RCC. Clinically, the majority of these tumors are incidentally found. Macroscopically, the tumor is well demarcated and consists of various-sized cysts. The fibrous septa are generally thin and there is no discernible expansile nodule. Microscopically, the cyst walls are lined with tumor cells with clear to occasionally slightly eosinophilic cytoplasm. The Fuhrman nuclear grade is generally low and usually corresponds to grade 1. The deletion of chromosome 3p was identified in most tumors using FISH analysis and VHL gene mutation was identified in 25% of MCRCC. As MCRCC generally exhibits a low stage of TNM classification, the great majority of these tumors have a favorable clinical course. To date, there are no reports of metastasis, vascular invasion or sarcomatoid change in MCRCC. Accordingly, nephron sparing surgery is first recommended as a therapeutic strategy.

  • Review of acquired cystic disease-associated renal cell carcinoma with focus on pathobiological aspects 査読

    Naoto Kuroda, Chisato Ohe, Shuji Mikami, Ondrej Hes, Michal Michal, Matteo Brunelli, Guido Martignoni, Yasuharu Sato, Tadashi Yoshino, Yoshiyuki Kakehi, Taro Shuin, Gang-Hong Lee

    HISTOLOGY AND HISTOPATHOLOGY   26 ( 9 )   1215 - 1218   2011年09月( ISSN:0213-3911

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Acquired cystic disease (ACD)-associated renal cell carcinoma (RCC) is a recently established entity. In this article, we introduce the general view of this new entity. Macroscopically, the disease exclusively occurs in ACD and may arise as a dominant mass or non-dominant masses. Histologically, the tumor is characterized by a microcystic pattern, neoplastic cells with an eosinophilic or oncocytic cytoplasm and frequent intratumoral oxalate crystal deposition. Prominent nucleoli of tumor cells are often observed. Immunohistochemically, neoplastic cells are generally positive for AMACR but negative for cytokeratin 7. Ultrastructurally, neoplastic cells contain abundant mitochondria in the cytoplasm. Genetically, the gain of chromosomes 3, 7, 17 and abnormality of the sex chromosome were frequently observed in several studies. In conclusion, ACD-associated RCC may be widely recognized as a distinct entity in the near future because this tumor is morphologically and genetically different from other renal tumor entities that have been previously established.

  • Review of juxtaglomerular cell tumor with focus on pathobiological aspect 査読

    Naoto Kuroda, Hiroko Gotoda, Chisato Ohe, Shuji Mikami, Keiji Inoue, Yoji Nagashima, Fredrik Petersson, Isabel Alvarado-Cabrero, Chin-Chen Pan, Ondrej Hes, Michal Michal, Zoran Gatalica

    DIAGNOSTIC PATHOLOGY   6   Article No.80   2011年08月( ISSN:1746-1596

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    Juxtaglomerular cell tumor (JGCT) generally affects adolescents and young adults. The patients experience symptoms related to hypertension and hypokalemia due to renin-secretion by the tumor. Grossly, the tumor is well circumscribed with fibrous capsule and the cut surface shows yellow or gray-tan color with frequent hemorrhage. Histologically, the tumor is composed of monotonous polygonal cells with entrapped normal tubules. Immunohistochemically, tumor cells exhibit a positive reactivity for renin, vimentin and CD34. Ultrastructurally, neoplastic cells contain rhomboid-shaped renin protogranules. Genetically, losses of chromosomes 9 and 11 were frequently observed. Clinically, the majority of tumors showed a benign course, but rare tumors with vascular invasion or metastasis were reported. JGCT is a curable cause of hypertensive disease if it is discovered early and surgically removed, but may cause a fatal outcome usually by a cerebrovascular attack or may cause fetal demise in pregnancy. Additionally, pathologists and urologists need to recognize that this neoplasm in most cases pursues a benign course, but aggressive forms may develop in some cases.

    DOI: 10.1186/1746-1596-6-80

  • 後天性嚢胞腎随伴腎細胞癌の1例 査読

    黒田 直人, 奈路田 拓史, 大江 知里, 三上 修治, 長嶋 洋治, 松嵜 理

    診断病理 : Japanese journal of diagnostic pathology   28 ( 2 )   137 - 140   2011年04月( ISSN:1345-6431

     詳細を見る

    掲載種別:記事・総説・解説・論説等(学術雑誌)  

    CiNii Article

  • 【腎腫瘍 up to date 2010s】 頻度の低い腎上皮性腫瘍

    大江知里, 黒田直人

    病理と臨床   28 ( 10 )   1053-1059 - 1066   2010年10月( ISSN:0287-3745

     詳細を見る

    担当区分:筆頭著者   掲載種別:記事・総説・解説・論説等(学術雑誌)  

    CiNii Article

▼全件表示

講演・口頭発表等

  • 淡明細胞型腎細胞癌の予後予測および治療戦略に繋がる組織形態解析

    大江 知里

    日本病理学会会誌  2023年10月  (一社)日本病理学会

  • LAG-3/FGL1の発現は尿路上皮癌における免疫チェックポイント阻害薬の効果と関連する

    吉田 崇, 中本 喬太, 厚海 奈穂, 大江 知里, 池田 純一, 安河内 彦輝, 蔦 幸治, 木下 秀文

    日本癌治療学会学術集会抄録集  2023年10月  (一社)日本癌治療学会

  • 腎癌術後再発因子の適切な病理学的評価のために必要な泌尿器科医と病理医の連携について

    大江知里

    第53回腎癌研究会   2023年07月 

  • 腎摘出術後に再発した症例におけるPD-L1の発現と予後解析 ARCHERY study

    玉田 聡, 野澤 昌弘, 大庭 康司郎, 水野 隆一, 高本 篤, 大江 知里, 松原 伸晃, 木村 剛, 冨田 善彦, 野々村 祝夫, 江藤 正俊

    腎癌研究会会報  2023年07月  (一社)腎癌研究会

  • カテーテル尿はどこまで踏み込むべきか? 尿細胞診の結果に基づく臨床的判断 腎温存療法の展望を含めて

    吉田 崇, 大江 知里

    日本臨床細胞学会雑誌  2023年05月  (公社)日本臨床細胞学会

  • 尿細胞診に悩む若手へ,ベテランよりの解決策 腎盂・尿管癌の尿細胞診 上部尿路洗浄尿や尿管カテーテル尿の再評価と疑問点

    西村 奏絵, 秦 直也, 伊藤 寛子, 山東 香織, 岡野 公明, 大江 知里, 蔦 幸治

    日本臨床細胞学会雑誌  2023年05月  (公社)日本臨床細胞学会

  • Pathology of non-clear cell RCC: Major revisions of the WHO2022 classification

    大江知里

    第110回日本泌尿器科学会総会  2023年04月 

  • 病理所見から腎癌の治療戦略にどこまで迫れるか?

    大江知里

    第110回日本泌尿器科学会総会  2023年04月 

  • 非淡明細胞型腎がんのすべて 非淡明細胞型腎癌の病理 WHO2022分類の主な改訂点(Pathology of non-clear cell RCC: Major revisions of the WHO2022 classification)

    Ohe Chisato

    日本泌尿器科学会総会  2023年04月  (一社)日本泌尿器科学会総会事務局

  • 肝転移を有する尿路上皮癌と免疫チェックポイント阻害薬 臨床的・分子遺伝学的検討(Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis)

    吉田 崇, 大江 知里, 伊藤 克弘, 高田 秀明, 齊藤 亮一, 北 悠希, 佐野 剛視, 蔦 幸治, 木下 秀文, 北村 寛, 西山 博之, 小林 恭

    日本泌尿器科学会総会  2023年04月  (一社)日本泌尿器科学会総会事務局

  • 腎細胞癌の病理学的予後因子の組織学的評価

    大江 知里

    日本病理学会会誌  2023年03月  (一社)日本病理学会

  • 腎細胞癌の術後再発因子の適切な病理学的評価のために必要な泌尿器科医と病理医の連携について

    大江知里

    第11回日本泌尿器病理研究会学術集会  2023年02月 

  • 尿路上皮癌の分類解説

    大江知里

    第21回泌尿器細胞診カンファレンス学術集会  2023年02月 

  • 尿路上皮癌の最近の話題と尿細胞診のピットフォール

    大江知里

    第47回日本臨床細胞学会近畿連合会学術集会  2022年12月 

  • 術後リンパ漏を呈した膀胱尿路上皮癌Plasmacytoid variantの1例

    秋山 恭二朗, 大杉 治之, 池田 純一, 福井 真二, 滝澤 奈恵, 谷口 久哲, 矢西 正明, 齊藤 亮一, 杉 素彦, 木下 秀文, 松田 公志, 河野 由美子, 狩谷 秀治, 大江 知里

    泌尿器科紀要  2022年12月  泌尿器科紀要刊行会

  • 病理医の視点から考える腎癌の術後再発リスク因子

    大江知里

    第8回日本泌尿器腫瘍学会  2022年11月 

  • 腎細胞癌の再発予測や治療効果予測につながる病理学的因子

    大江知里

    第72回日本泌尿器科学会中部総会  2022年10月 

  • 卵巣癌肺転移に対するラジオ波焼灼療法(RFA)で医原性気胸を発症し膿胸に至った1例

    松井 浩史, 日野 春秋, 内海 貴博, 丸 夏未, 谷口 洋平, 齊藤 朋人, 村川 知弘, 大江 知里, 蔦 幸治

    肺癌  2022年10月  (NPO)日本肺癌学会

  • 肝転移を有する尿路上皮癌と免疫チェックポイント阻害薬 臨床的・分子遺伝学的検討

    吉田 崇, 大江 知里, 伊藤 克弘, 高田 秀明, 齊藤 亮一, 北 悠希, 佐野 剛視, 蔦 幸治, 木下 秀文, 北村 寛, 西山 博之, 小林 恭

    日本癌治療学会学術集会抄録集  2022年10月  (一社)日本癌治療学会

  • 診断が困難であった嚢胞性褐色細胞腫の1例

    川西 誠, 神尾 絵里, 谷口 久哲, 大江 知里, 清田 翔, 中尾 一慶, 佐藤 五郎, 増尾 友紀, 池田 純一, 大杉 治之, 滝沢 奈恵, 矢西 正明, 斎藤 亮一, 渡辺 仁人, 杉 素彦, 木下 秀文, 松田 公志, 田中 満, 久保田 恵子

    泌尿器科紀要  2022年08月  泌尿器科紀要刊行会

  • 腎癌取り扱い規約第5版の改訂点のポイント 病理学的予後因子を中心に

    大江 知里

    腎癌研究会会報  2022年07月  (一社)腎癌研究会

  • 頭蓋内Solitary fibrous tumorの膵転移の1例

    西村 奏絵, 秦 直也, 山東 香織, 岡野 公明, 野田 百合, 岡部 麻子, 宮坂 知佳, 大江 知里, 石田 光明, 蔦 幸治

    日本臨床細胞学会雑誌  2022年05月  (公社)日本臨床細胞学会

  • 非淡明細胞型腎細胞癌に対するドライバー遺伝子を含む融合遺伝子の探索 国内会議

    ◎大江知里, 宇野礼奈, 池田純一, 厚海奈穂, 吉田真子, 黒田直人, 蔦幸治

    第111回病理学会総会  2022年04月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:兵庫県神戸市  

  • 最近の泌尿器・生殖器腫瘍の話題~改訂された癌取扱い規約とWHO分類を中心に~ 腎癌取扱い規約第5版とWHO分類第5版の改訂ポイント

    大江知里

    日本病理学会総会  2022年04月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  • 腎原発Ewing肉腫の1例

    中尾 一慶, 松崎 和炯, 吉田 崇, 清田 翔, 川西 誠, 佐藤 五郎, 増尾 有紀, 神尾 絵里, 池田 純一, 大杉 治之, 滝沢 奈恵, 谷口 久哲, 矢西 正明, 齊藤 亮一, 渡辺 仁人, 杉 素彦, 木下 秀文, 松田 公志, 大江 知里, 奥廣 有喜

    泌尿器科紀要  2022年01月  泌尿器科紀要刊行会

  • カンファレンスの検討から発展した研究成果と今後の展望

    ◎大江知里

    Kansai Prostate Cancer Symposium  2021年12月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:web  

  • 淡明腎細胞癌における好酸性領域は、新生血管阻害薬や免疫チェックポイント阻害薬の奏功と関係する 国内会議

    吉田崇, 大江知里, 池田純一, 大杉治之, 杉素彦, 松田公志, 木下秀文

    第109回日本泌尿器科学会総会  2021年12月  大家

     詳細を見る

    会議種別:ポスター発表  

    開催地:横浜市 パシフィコ横浜  

  • 病理学的観点から術後補助療法を必要とする症例を選別できる可能性

    ◎大江知里

    MSD株式会社 メディカルアフェアーズ アドバイザリー会議  2021年12月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:web  

  • 淡明腎細胞癌における好酸性領域は、新生血管阻害薬や免疫チェックポイント阻害薬の奏功と関連する

    吉田 崇, 大江 知里, 池田 純一, 大杉 治之, 杉 素彦, 松田 公志, 木下 秀文

    日本泌尿器科学会総会  2021年12月  (一社)日本泌尿器科学会総会事務局

  • ここが変わった!腎癌取扱い規約第5版~病理学的事項の改訂ポイント~ 国内会議

    ◎大江知里

    第51回 腎癌研究会 教育講演  2021年11月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:web  

  • EUS-FNA後needle tract seedingによる胃転移を来した膵癌の2例

    高山 昇之, 高岡 亮, 池浦 司, 三好 秀明, 光山 俊行, 伊藤 嵩志, 中丸 洸, 桝田 昌隆, 鈴木 亮, 岡崎 敬, 島谷 昌明, 長沼 誠, 山本 智久, 山木 壮, 坂口 達馬, 里井 壯平, 副田 美希, 三木 博和, 道浦 拓, 大江 知里

    日本消化器病学会雑誌  2021年10月  (一財)日本消化器病学会

  • 腎尿路系腫瘍の病理診断~最近の話題を含めて~

    ◎大江知里

    静岡県立がんセンター専門病理医養成研修会  2021年09月 

     詳細を見る

    開催地:web  

  • Integration of Neuropilin 1, Regulator of G Protein Signalling 5, and Forkhead Box M1 Expression and Tumour Necrosis as a Prognostic Classifier based on Molecular Subtypes of Clear Cell Renal Cell Carcinoma 国際会議

    Yoshida T, Ohe C, Ikeda J, Saito R, Ohsugi H, Sugi M, Kinoshita H, Matsuda T

    米国泌尿器科学会議(AUA2021)  2021年09月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:WEB開催  

  • 腎癌取り扱い規約第5版の改訂ポイント ~病理学的予後因子を中心に~ 国内会議

    ◎大江知里

    第51回腎癌研究会教育セミナー  2021年07月 

     詳細を見る

    開催地:web  

  • 腎泌尿器癌の病理診断のup-to-date~腎癌取扱い規約第5版の改訂点も含めて~ 国内会議

    ◎大江知里

    第11回阪神病理症例検討会特別講演会  2021年06月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:web  

  • 淡明細胞型腎細胞癌に対する ClearCode34 molecular subtypeの臨床病理学的意義に関する検討 国内会議

    ◎大江知里, 吉田崇, 大杉治之, 池田純一, 蔦幸治

    第110回日本病理学会総会  2021年04月  日本病理学会

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:web  

  • 尿路上皮癌UPDATEセミナー:診断と治療の最前線第二回 『尿路上皮癌の病理』Molecular subtype (variant)の最近の話題 国内会議

    ◎大江知里

    日本泌尿器腫瘍学会 「URO-ONCOLOGY HUB」Webセミナー  2021年04月  日本泌尿器腫瘍学会

     詳細を見る

    開催地:web  

  • 腎泌尿器腫瘍;病理と治療のクロストーク最前線 免疫療法の時代に注目すべき膀胱癌の病理所見 分子サブタイプや腫瘍微小環境を含めて

    大江 知里

    日本病理学会会誌  2021年03月  (一社)日本病理学会

  • 暫定原発不明がんのPET/CTで腎癌が特定できた2症例

    河野 由美子, 宇都宮 啓太, 田井 格, 上埜 泰寛, 丸山 薫, 大江 知里, 滝沢 奈恵, 谷川 昇

    核医学  2021年  (一社)日本核医学会

  • Detection of multiple cutaneous leiomyomas can bring the diagnosis of hereditary leiomyomatosis and renal cancer 国際会議

    ◎Chisato Ohe

    第32回ESP Congress/第33回IAP Congress  2020年12月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:web  

  • がんゲノム医療におけるバイオバンクセンターと連携した革新的治療法の開発に向けたパイロットモデルの構築

    神田 晃, 蔦 幸治, 大江 知里, 田中 顕之, 日笠 幸一郎, 松田 達志, 鈴木 健介, 岩井 大, 塚口 裕康, 松田 公志, 木下 秀文, 仲野 俊成

    関西医科大学雑誌  2020年12月  関西医科大学医学会

  • 限局性腎癌におけるGeriatric nutritional risk index(GNRI)の術前予後予測因子としての有用性の検討 国内会議

    ◎神尾絵里, 吉田崇, 大江知里, 大杉治之, 杉素彦, 木下秀文, 松田公志

    第70回日本泌尿器科学会中部総会  2020年11月  宮澤克人

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:金沢市 石川県音楽堂+web開催  

  • 日本人における、淡明腎細胞癌に対するClearCode34 Molecular subtypesの有用性 国内会議

    ◎吉田崇, 大江知里, 池田純一, 谷口久哲, 大杉治之, 杉素彦, 木下秀文, 松田公志

    日本泌尿器主要学会第6回学術集会  2020年10月  堀江重郎

     詳細を見る

    会議種別:ポスター発表  

    開催地:京都市 京都市勧業館みやこめっせ  

  • 前立腺癌のprecision medicineに向けた泌尿器科医と病理医の連携の重要性 国内会議

    ◎大江 知里

    第6回日本泌尿器腫瘍学会学術集会  2020年10月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:京都  

  • 腎細胞癌におけるPD-L1 (clone 73-10)の発現と予後予測の検討 国内会議

    池田 純一, 大江 知里, 吉田 崇, 大杉治之, 杉 素彦, 木下 秀文, 蔦 幸治, 松田 公志

    第58回癌治療学会学術集会  2020年10月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:京都  

  • 腎腫瘍の免疫染色 招待 国内会議

    ◎大江 知里

    第9回神戸免疫組織診断セミナー  2020年10月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:web  

  • PBRM1発現を組み込んだ淡明細胞型腎細胞癌の術後再発を予測するスコアリングシステム

    大杉 治之, 大江 知里, 吉田 崇, 池田 純一, 杉 素彦, 木下 秀文, 蔦 幸治, 松田 公志

    日本癌治療学会学術集会抄録集  2020年10月  (一社)日本癌治療学会

  • 腎細胞癌におけるPD-L1(clone73-10)の発現の有無と予後予測の検討

    池田 純一, 大江 知里, 吉田 崇, 大杉 治之, 杉 素彦, 木下 秀文, 蔦 幸治, 松田 公志

    日本癌治療学会学術集会抄録集  2020年10月  (一社)日本癌治療学会

  • A novel scoring system integrating PBRM1 expression to predict recurrence in patients with non-metastatic clear cell renal cell carcinoma undergoing radical surgery. 国際会議

    ◎Ohsugi H, Ohe C, Yoshida T, Ikeda J, Kinoshita H, Matsuda T

    第35回欧州泌尿器科科学会議(European Association of Urology2020)  2020年07月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:アムステルダム、オランダ(Web開催)  

  • 広範なオンコサイト化生を伴った多形腺腫の1例

    伊藤 寛子, 山東 香織, 岡野 公明, 蛭子 佑翼, 宮坂 知佳, 大江 知里, 石田 光明, 蔦 幸治

    日本臨床細胞学会雑誌  2020年05月  (公社)日本臨床細胞学会

  • 当院における縦隔リンパ節病変に対する超音波気管支鏡下針生検(EBUS-TBNA)症例の検討

    山東 香織, 岡野 公明, 伊藤 寛子, 岡本 久, 石田 光明, 宮坂 知佳, 大江 知里, 蔦 幸治

    日本臨床細胞学会雑誌  2020年05月  (公社)日本臨床細胞学会

  • 当院で経験した嗅神経芽細胞腫8症例の細胞学的検討

    岡野 公明, 伊藤 寛子, 山東 香織, 岡本 久, 石田 光明, 宮坂 知佳, 大江 知里, 蔦 幸治

    日本臨床細胞学会雑誌  2020年05月  (公社)日本臨床細胞学会

  • Triple negative breast cancerにおけるadipophilinの発現と予後についての検討

    吉川 勝広, 石田 光明, 大江 知里, 宮坂 知佳, 田中 顕之, 石田 佳央理, 植村 芳子, 関本 貢嗣, 杉江 知治, 蔦 幸治

    日本病理学会会誌  2020年03月  (一社)日本病理学会

  • 腋窩に発生したsignet-ring cell/histiocytoid carcinomaの一例

    伊藤 唯, 大江 知里, 石田 光明, 宮坂 知佳, 蔦 幸治

    日本病理学会会誌  2020年03月  (一社)日本病理学会

  • 涙嚢に発生した導管癌の1例

    宮坂 知佳, 石田 光明, 大江 知里, 石田 佳央理, 蔦 幸治

    日本病理学会会誌  2020年03月  (一社)日本病理学会

  • 婦人科領域の遺伝性腫瘍UP-TO-DATE 遺伝性平滑筋腫症腎細胞癌の臨床病理学的特徴

    黒田 直人, 大江 知里, 三上 修治, 古屋 充子, 長嶋 洋治

    日本病理学会会誌  2020年03月  (一社)日本病理学会

  • 嫌色素性腎細胞癌に特徴的な染色体異常と組織亜型との関係 国内会議

    ◎大橋瑠子, 大江知里, 黒田直人, 都築豊徳, 長嶋洋治, 味岡洋一

    第9回泌尿器病理研究会学術集会  2020年02月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:東京  

  • 神経内分泌分化を伴う前立腺癌の3例 国内会議

    ◎池田純一, 大江知里, 木下秀文, 蔦幸治, 松田公志

    第9回泌尿器病理研究会学術集会  2020年02月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:東京  

  • 原発巣治癒後、急激な遠隔転移を認めた非筋層浸潤性膀胱がんの1例

    吉田 崇, 木下 秀文, 増尾 有紀, 佐藤 五郎, 松下 純, 元木 裕典, 大杉 治之, 井上 貴昭, 吉田 健志, 谷口 久哲, 矢西 正明, 渡辺 仁人, 杉 素彦, 松田 公志, 大江 知里

    泌尿器科紀要  2020年02月  泌尿器科紀要刊行会

  • ホルモン治療後の前立腺癌の形態変化~免疫形質と臨床像の対比~ 国内会議

    ◎大江知里, 池田純一

    Kansai Prostate Cancer Symposium  2019年12月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:大阪  

  • 尿路上皮癌の分子生物学的分類を用いた症例選択の可能性 国内会議

    ◎大江知里

    名古屋市立大学 Scientific Exchange Meeting  2019年11月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:名古屋市  

  • 尿路上皮癌の新たな治療戦略に求められる病理診断~分子生物学的分類に基づいて~ 国内会議

    ◎大江知里

    第65回日本病理学会秋期特別総会  2019年11月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:つくば市  

  • 当院における分泌癌症例の臨床病理・分子遺伝学的検討

    鈴木 健介, 原田 博史, 武田 真幸, 植村 芳子, 大江 知里, 河原 明彦, 澤田 俊輔, 岩井 大

    日本唾液腺学会誌  2019年11月  日本唾液腺学会

  • 鑑別に困難であった下大静脈浸潤を伴う副腎腫瘤の1例 国内会議

    佐藤五郎, 吉田崇, 川西誠, 清田翔, 中尾一慶, 増尾有紀, 神尾絵里, 松崎和炯, 大杉治之, 滝澤奈恵, 谷口久哲, 矢西正明, 齊藤亮一, 渡辺仁人, 杉素彦, 木下秀文, 松田公志, 大江知里

    第242回日本泌尿器科学会関西地方会  2019年10月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:河内長野市 大阪南医療センター附属大阪南看護学校内  

  • 細胞診断に苦慮した縦隔原発滑膜肉腫の1例

    吉岡 紗弥, 蛭子 佑翼, 岡本 久, 石田 光明, 宮坂 知佳, 田中 顕之, 大江 知里, 蔦 幸治

    日本臨床細胞学会雑誌  2019年10月  (公社)日本臨床細胞学会

  • 本邦の遺伝性平滑筋腫症-腎細胞癌症候群(HLRCC)10家系における腎癌と関連疾患の病態、および遺伝カウンセリング

    古屋 充子, 蓮見 壽史, 中井川 昇, 神戸 直智, 大江 知里, 長嶋 洋治, 矢尾 正祐

    日本遺伝カウンセリング学会誌  2019年07月  (一社)日本遺伝カウンセリング学会

  • Search for morphological features associated with molecular abnormality of high-grade renal cancers (学術奨励賞受賞講演) 国内会議

    ◎大江知里

    第108回日本病理学会総会  2019年05月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:東京  

  • 【病理医と臨床医の関わり方~進行性尿路上皮癌の薬物療法を例に考える~】尿路上皮癌の新たな治療戦略に役立つ病理診断-免疫染色の有用性と問題点- 国内会議

    ◎大江知里

    第108回日本病理学会総会  2019年05月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:東京  

  • FH 欠損腫瘍10 例の遺伝学的、疫学的、臨床病理学的検討:HLRCC との関連を含めて 国内会議

    ◎古屋充子, 大江知里, 黒田直人, 田中玲子, 長嶋洋治

    第108回日本病理学会総会  2019年05月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:東京  

  • 【希少組織型を含む腎癌新規組織型診断のために】希少腎細胞癌 国内会議

    ◎大江知里

    第108回日本病理学会総会  2019年05月 

     詳細を見る

    開催地:東京  

  • 【腎癌病理の最前線】病理学的予後因子を中心に 国内会議

    ◎大江知里

    第108回日本病理学会総会  2019年05月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:東京  

  • 【臓器別病理診断講習会】 内反性増殖を示す尿路上皮性腫瘍の病理診断 国内会議

    ◎大江知里

    第108回日本病理学会総会  2019年05月 

     詳細を見る

    開催地:東京  

  • 当院で経験した多形腺腫由来癌の細胞学的検討

    岡野 公明, 山東 香織, 岡本 久, 石田 光明, 田中 顕之, 宮坂 知佳, 大江 知里, 蔦 幸治

    日本臨床細胞学会雑誌  2019年05月  (公社)日本臨床細胞学会

  • 当院における胃粘膜下腫瘍に対するEUS-FNA実施症例の検討

    山東 香織, 岡野 公明, 岡本 久, 石田 光明, 田中 顕之, 宮坂 知佳, 大江 知里, 蔦 幸治

    日本臨床細胞学会雑誌  2019年05月  (公社)日本臨床細胞学会

  • FH欠損腫瘍10例の遺伝学的、疫学的、臨床病理学的検討 HLRCCとの関連を含めて

    古屋 充子, 大江 知里, 黒田 直人, 田中 玲子, 長嶋 洋治

    日本病理学会会誌  2019年04月  (一社)日本病理学会

  • 内反性増殖を示す尿路上皮性腫瘍の病理診断

    大江 知里

    日本病理学会会誌  2019年04月  (一社)日本病理学会

  • 臓器病理学の最近の進歩 泌尿器腫瘍病理の最前線 腎癌病理の最前線 病理学的予後因子を中心に

    大江 知里

    日本病理学会会誌  2019年04月  (一社)日本病理学会

  • 肺原発と考える類上皮血管肉腫の1例

    田中 顕之, 石田 佳央理, 宮坂 知佳, 大江 知里, 石田 光明, 村川 知弘, 蔦 幸治

    日本病理学会会誌  2019年04月  (一社)日本病理学会

  • 手関節に発生した砂粒小体様石灰沈着を伴う腱滑膜炎の一例

    宮坂 知佳, 石田 光明, 浜田 佳孝, 外山 雄康, 大江 知里, 石田 佳央理, 田中 顕之, 蔦 幸治

    日本病理学会会誌  2019年04月  (一社)日本病理学会

  • 両側腎癌術後に皮膚病変を認め、Fumarate hydratase遺伝子検査にて診断が確定したHereditary leiomyomatosis and RCCの1例

    小糸 悠也, 木下 秀文, 吉田 健志, 神尾 絵里, 島田 誠治, 谷口 久哲, 井上 貴明, 矢西 正明, 駒井 資弘, 渡邊 仁人, 杉 素彦, 松田 公志, 大江 知里, 松田 智子, 神戸 直智, 古屋 充子

    泌尿器科紀要  2019年03月  泌尿器科紀要刊行会

  • 嚢胞性腎癌との鑑別が困難であった内反型尿路上皮癌の1例

    岡 利樹, 田中 亮, 山中 庸平, 金城 孝則, 惣田 哲次, 吉岡 厳, 高田 晋吾, 安岡 弘直, 長嶋 洋治, 大江 知里

    泌尿器科紀要  2019年03月  泌尿器科紀要刊行会

  • 胸部の平滑筋腫の生検を契機に確定診断し得た遺伝性平滑筋腫症-腎細胞癌症候群の1家系

    松田 智子, 神戸 直智, 植田 郁子, 山崎 文和, 岡本 祐之, 大江 知里, 吉田 健志, 木下 秀文, 古屋 充子

    日本皮膚科学会雑誌  2019年02月  (公社)日本皮膚科学会

  • 当院での過去10年間の腎腫瘍診断を振り返って ~組織型分類を含めた病理学的な予後因子のup-to-date~ 国内会議

    ◎大江知里

    Kansai Prostate Cancer Symposium  2018年10月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:大阪  

  • 【小径腎腫瘍に対して病理はどのように対峙すべきか】小径腎腫瘍の病理診断、特に針生検 国内会議

    ◎大江知里

    第107回日本病理学会総会  2018年06月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:北海道  

  • Follicular pancreatitis 3例の臨床病理学的特徴及び網羅的遺伝子解析. 国内会議

    ◎石田光明, 良田大典, 大江知里, 宮坂知佳, 柳本泰明, 里井壮平, 蔦 幸治

    第107回日本病理学会総会.  2018年06月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:札幌  

  • 胆嚢原発の肝様分化を示す淡明細胞腺癌の1例. 国内会議

    ◎宮坂知佳, 石田光明, 大江知里, 宮川文, 蔦幸治

    第107回日本病理学会総会.  2018年06月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:札幌  

  • 【臓器横断的病理診断から読み解く「がん関連症候群」】遺伝性平滑筋腫症―腎細胞癌症候群(HLRCC)の病理 国内会議

    ◎大江知里

    第107回日本病理学会総会  2018年06月 

     詳細を見る

    開催地:北海道  

  • Atypical polypoid adenomyoma 6例の細胞学的特徴の検討 国内会議

    ◎有本知子, 蛭子佑翼, 石田光明, 宮坂知佳, 大江知里, 宮川文, 蔦幸治

    第59回日本臨床細胞学会春期大会  2018年06月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:札幌  

  • 当院で診断された子宮頸部・子宮体部原発神経内分泌癌症例の検討. 国内会議

    ◎蛭子佑翼, 岡本久, 石田光明, 宮坂知佳, 大江知里, 宮川文, 蔦幸治

    第59回日本臨床細胞学会春期大会  2018年06月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:札幌  

  • 両側腎癌術後に皮膚病編を認め、fumarate hydratase(FH)遺伝子検査にて診断が確定したHereditary leiomyomatosis and RCC(HLRCC) の1例 国内会議

    小糸悠也, 吉田健志, 神尾絵里, 島田誠治, 谷口久哲, 井上貴昭, 矢西正明, 駒井資弘, 渡辺仁人, 杉素彦, 木下秀文, 大江知里, 神戸直智, 松田公志

    第237回日本泌尿器科学会関西地方会  2018年02月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:西宮市 西宮市民会館  

  • Renal tumor with multilocular cystic appearance 国際会議

    ◎Chisato Ohe, Naoto Kuroda

    The15th Japan-Korea Joint Slide Conference of International Academy of Pathology (IAP)  2017年12月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:兵庫県  

  • 当院で経験した子宮内膜肉腫の細胞学的検討と細胞診術前診断の意義 国内会議

    ◎岡野公明, 宮川文, 石田光明, 宮坂知佳, 大江知里, 蔦幸治

    第56回日本臨床細胞学会総会 (秋期大会)  2017年11月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:福岡  

  • プロフェッショナルな医師を目指して~アメリカでの挑戦と収穫~ 国内会議

    ◎大江知里

    日本病理学会 中部支部夏の学校  2017年08月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:愛知  

  • A reappraisal of morphologic differences between renal medullary carcinoma and collecting duct carcinoma after exclusion of newer subtypes of renal cell caricinoma : Report from the High-grade Distal Nephron Adenocarcinoma (HDNA) International Consortium 国際会議

    ◎Chisato Ohe, and HDNA International Consortium

    2016 Annual Meeting, United States and Canadian Academy of Pathology (USCAP)  2016年03月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:Seattle,USA  

  • Prostate cancer with overlapping features of small cell carcinoma and acinar adenocarcinoma: A critical appraisal of morphology and correlation with immunohistochemical markers 国際会議

    Deepika Sirohi, Steven Smith, Chisato Ohe, Mariza de Peralta-Venturina, Daniel Luthringer, Scott A Tomlins, Moushumi Suryavanshi, Arkadiusz Gertych, Beatrice Knudsen, Mahul B Amin.

    2016 Annual Meeting, United States and Canadian Academy of Pathology (USCAP)  2016年03月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:Seattle, USA  

  • A novel low grade morphologic variant of hereditary leiomyomatosis-renal cell carcinoma syndrome-associated renal cell carcinoma (HLRCC-RCC)? 国際会議

    Steven Smith, Deepika Sirohi, Chisato Ohe, Jonathan McHugh, Jason Hornick, Jigna Kalariya, Sushil Karia, Katie Snape, Shirley Hodgson, Scott Tomlins, Rohit Mehra, Mahul B Amin.

    2016 Annual Meeting, United States and Canadian Academy of Pathology (USCAP)  2016年03月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:Seattle, USA  

  • 当院におけるASC-H判定の検討 国内会議

    ◎有元知子, 坂井仁美, 宮坂知佳, 大江知里, 坂井田紀子, 植村芳子, 鷹巣晃昌

    第53回日本臨床細胞学会秋期大会  2014年11月 

     詳細を見る

    開催地:下関  

  • 卒後10年を迎えて~病理医として母として皆さんに伝えたいこと~ 国内会議

    ◎大江知里

    日本病理学会 近畿支部夏の学校  2014年08月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:京都  

  • Unique differentiation of chromophobe renal cell carcinoma 国際会議

    ◎Chisato Ohe, Naoto Kuroda

    3rd Urogenital Pathology Meeting in Czech Republic  2014年06月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:Mikulov, Czech  

  • 当院における異型腺細胞(AGC)の細胞診断と組織診断との比較検討 国内会議

    ◎山東香利, 坂井仁美, 宮坂知佳, 大江知里, 坂井田紀子, 植村芳子, 鷹巣晃昌

    第55回日本臨床細胞学会総会(春季大会)  2014年06月 

     詳細を見る

    開催地:横浜  

  • 【腎腫瘍診断のための免疫染色】多様な組織型分類、治療戦略にも応用できる免疫染色 国内会議

    ◎大江知里, 黒田直人, 長嶋洋治

    第103回日本病理学会総会  2014年04月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:広島  

  • 胃型の形質発現を示す腫瘍性病変 国内会議

    ◎宮坂知佳, 坂井田紀子, 中野麗香, 大江知里, 鷹巣晃昌, 植村芳子

    第103回日本病理学会総会  2014年04月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:広島  

  • 胸腺上皮性腫瘍におけるリンパ球マーカーの発現意義 国内会議

    ◎保坂直樹, 大江知里, 宮坂知佳, 坂井田紀子, 植村芳子, 齊藤幸人, 池原進, 高橋伯夫

    第103回日本病理学会総会  2014年04月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:広島  

  • 腎腫瘍の病理学 国内会議

    ◎大江知里

    土佐診断病理セミナー  2014年02月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:高知  

  • EUS-FNAにて診断した膵内分泌腫瘍7例についての検討 国内会議

    ◎本里知子, 坂井仁美, 山東香織, 田口香利, 岡野公明, 岡本久, 大江知里, 宮坂知佳, 坂井田紀子, 植村芳子, 鷹巣晃昌

    第52回日本臨床細胞学会秋季大会  2013年11月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:大阪  

  • 膀胱小細胞癌と尿路上皮癌の鑑別に有用な所見の検討 国内会議

    ◎蛭子佑翼, 坂井仁美, 岡野公明, 岡本久, 本里知子, 大江知里, 坂井田紀子, 植村芳子, 鷹巣晃昌

    第52回日本臨床細胞学会秋季大会  2013年11月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:大阪  

  • 【腎癌up to date 個別化医療を目指して】腎腫瘍診断のための免疫組織化学 国内会議

    ◎大江知里, 黒田直人

    第102回日本病理学会総会  2013年06月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:北海道  

  • 腎腫瘍の多彩性,奥深さに魅せられて(公募部門学術奨励賞受賞講演) 国内会議

    ◎大江知里

    第61回日本病理学会近畿支部学術集会  2013年05月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

    開催地:大阪  

  • EUS-FNA導入による病理学的膵癌診断率の変化 国内会議

    ◎山木壮, 里井壯平, 豊川秀吉, 柳本泰明, 山本智久, 池浦司, 島谷昌明, 高岡亮, 岡崎和一, 大江知里, 植村芳子, 坂井田紀子, 由井倫太郎, 廣岡智, 道浦拓, 井上健太郎, 權雅憲

    第113回日本外科学会定期学術集会  2013年04月 

     詳細を見る

    開催地:福岡  

  • 乳管内洗浄細胞診の有用性について 国内会議

    ◎山東香織, 坂井仁美, 本里知子, 田口香利, 岡野公明, 宮坂知佳, 大江知里, 坂井田紀子, 植村芳子, 鷹巣晃昌

    第51回日本臨床細胞学会秋季大会  2012年11月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:新潟  

  • 篩状構造を特徴とする腺様嚢胞癌と基底細胞腺癌の比較検討 国内会議

    ◎岡野公明, 坂井仁美, 山東香織, 田口香利, 岡本 久, 宮坂知佳, 大江知里, 坂井田紀子, 植村芳子, 鷹巣晃昌

    第51回日本臨床細胞学会秋季大会  2012年11月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:新潟  

  • Fine needle asperationの積極導入により膵癌術前診断率の改善 国内会議

    ◎山木 壮,里井壯平,豊川秀吉,柳本泰明,山本智久,池浦 司,島谷昌明,高岡 亮,岡崎和一,大江知里,植村芳子,坂井田紀子,由井倫太郎,廣岡 智,權 雅憲

    第20回日本消化器関連学会週間  2012年10月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:神戸  

  • 免疫組織化学的にTFE3強陽性を示した腎類上皮血管筋脂肪腫の一例 国内会議

    ◎大江 知里, 黒田 直人, 田中 祐吉, 田中 水緒, 保坂 直樹, 中野 麗香, 宮坂 知佳, 坂井田 紀子, 植村 芳子

    第101回日本病理学会総会  2012年04月 

     詳細を見る

    開催地:東京  

  • 耳下腺に発生した基底細胞線癌と基底細胞線種の細胞学的検討 国内会議

    ◎岡野公明, 坂井仁美, 山東香織, 岡本久, 本里知子, 宮坂知佳, 大江知里, 坂井田紀子, 植村芳子, 鷹巣晃昌

    第52回日本臨床細胞学会春期大会  2011年05月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:福岡  

  • 嫌色素性腎細胞癌とオンコサイトーマの免疫組織化学的手法を用いた比較検討. 国内会議

    ◎大江知里, 黒田直人, 四方伸明, 圦貴司, 仙崎英人, 鷹巣晃昌, 田所知佳, 中野麗香, 坂井田紀子, 植村芳子.

    第100回日本病理学会  2011年04月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:東京  

  • 当院における膵癌に対する内視鏡的組織・細胞診断率の変遷 国内会議

    ◎山木 壮,里井壯平,豊川秀吉,柳本泰明,山本智久,池浦 司,島谷昌明,高岡 亮,岡﨑和一,大江知里,植村芳子,坂井田紀子,由井倫太郎,廣岡 智,權 雅憲

    第72回日本臨床外科学会総会  2010年11月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:横浜  

  • 膵癌における治療前組織・細胞診断率の改善策 国内会議

    ◎山木 壮,里井壯平,豊川秀吉,柳本泰明,山本智久,池浦 司,島谷昌明,高岡 亮,岡﨑和一,大江知里,植村芳子,坂井田紀子,由井倫太郎,廣岡 智

    日本消化器病学会近畿支部第93回例会  2010年09月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:大阪  

  • 当院における局所進行ならびに切除可能膵癌症例の術前診断の現状 国内会議

    ◎山木 壮,里井壯平,豊川秀吉,柳本泰明,山本智久,由井倫太郎,高岡 亮,岡﨑和一,大江千里,植村芳子, 坂井田紀子,權 雅憲

    第40回日本膵臓学会大会  2009年07月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:東京  

  • 小児機能性副腎皮質腫瘍の一例 国内会議

    ◎大江知里, 田所知佳, 中野麗香, 坂井田紀子, 植村芳子

    第98回日本病理学会総会  2009年05月 

     詳細を見る

    会議種別:ポスター発表  

    開催地:京都  

  • 脾腫瘍の一例 国内会議

    ◎大江知里, 坂井田紀子, 田所知佳, 鷹巣晃昌, 植村芳子

    第45回日本病理学会近畿支部学術集会  2009年05月 

     詳細を見る

    開催地:大阪  

  • 鼻腔腫瘍の一例 国内会議

    ◎大江知里, 坂井田紀子, 植村芳子

    日本病理学会近畿支部第41回学術集会  2008年05月 

     詳細を見る

    開催地:大阪  

  • Cardiac coilを用いたMRIにおける前立腺癌病巣の描出能:病理標本との比較検討 国内会議

    ◎黒川弘晶, 野村基雄, 桑田さおり, 藤田あすか, 前原稔, 大村直人, 池田茂樹, 澤田敏, 大江知里, 坂井田紀子

    第67回日本医学放射線学会総会  2008年04月 

     詳細を見る

    会議種別:口頭発表(一般)  

    開催地:横浜  

▼全件表示

科研費

  • 組織表現型に基づいた腎癌オルガノイドの樹立と新規治療戦略の創出

    基盤研究(C)  2023年

  • 浸潤性膀胱癌における新規治療ターゲットとしての一次繊毛

    基盤研究(C)  2020年

  • 高悪性度腎細胞癌の治療薬シーズの探索

    若手研究  2019年

共同研究(外部資金獲得実績のあるもの)

  • 人工知能を活用した病理組織画像による予後予測システムの開発

    学校法人関西医科大学KMU研究コンソーシアム  2020年

  • 腎癌・腎腫瘍の臨床病理学的検討とゲノム病理データベース構築

    2018年

奨励寄附金・助成金

  • 腎癌の癌微小環境に関連する網羅的遺伝子解析とバイオマーカーの同定

    大阪対がん協会  2020年

  • 腎細胞癌における治療標的遺伝子の探索と臨床病理学的特徴の解析

    一般社団法人加多乃会  2019年

  • 腎癌の分子病理学的解析と臨床的意義の検討

    公益財団法人上原記念生命科学財団  2015年

その他補助金等

  • 若手医師のキャリア形成につながる病理学的な研究支援体制の構築

    一般社団法人加多乃会  2023月

担当教育概要

  • 基礎と臨床の架け橋となる病理学教育に加え、医師のキャリア支援や国際的学術交流にも参画し、プロフェッショナル意識の高い良医育成にも力を入れてきた。
    <2023年度までの担当科目>
    医学部医学科1学年:医療プロフェッショナリズムの実践, リサーチマインド実践セミナー
    医学部医学科2学年:病因と病態A2
    医学部医学科3学年:腎尿路コース, 周産期・生殖器コース
    医学部医学科4学年:臨床実習入門「医師のキャリア形成」
    医学部医学科5学年:海外提携校との国際合同講義, 病理診断科臨床実習
    医学部医学科6学年:病理診断科臨床実習, まとめの講義

社会貢献活動

  • 病理診断と治療に伴う前立腺がんの形態変化

    役割:講師

    前立腺がん患者・家族の会~腺友倶楽部~  Mo-FESTA CANCER FORUM